Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in genes encoding il33 and il1RL1

By detecting specific genetic risk alleles in IL33 and IL1RL1 and using IL33 and IL-4R antagonists, the method addresses diagnostic and treatment challenges for asthma, COPD, and ACOS, enhancing precision in identifying and treating eosinophilic subsets.

JP2024163308AInactive Publication Date: 2024-11-21REGENERON PHARMACEUTICALS INC
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
JP2024158740
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2017-04-13
Filing Date
2024-09-13
Publication Date
2024-11-21
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current diagnostic and treatment challenges exist for differentiating between asthma, chronic obstructive pulmonary disease (COPD), and asthma-COPD overlap syndrome (ACOS), as well as accurately identifying eosinophil subsets of these disorders, due to overlapping symptoms and resistance to standard treatments like corticosteroids and IL-5 therapy.

Method used

The method involves detecting specific risk alleles in the IL33 and IL1RL1 genes, such as rs1342326 and rs1420101, and administering IL33 antagonists and IL-4R antagonists to treat or inhibit eosinophilic asthma, COPD, and ACOS, using IL33 traps or antibodies that specifically bind IL33, and IL-4R antibodies that specifically bind IL-4R.

Benefits of technology

This approach allows for precise identification and treatment of eosinophilic asthma, COPD, and ACOS by targeting specific genetic markers, thereby improving diagnostic accuracy and treatment efficacy for these conditions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024163308000014
    Figure 2024163308000014
  • Figure 2024163308000015
    Figure 2024163308000015
  • Figure 2024163308000016
    Figure 2024163308000016
Patent Text Reader

Abstract

To provide pharmaceuticals for treatment and inhibition of inflammatory lung diseases in patients having risk alleles in genes encoding IL33 and IL1RL1.SOLUTION: A pharmaceutical for use in treating or inhibiting nasal polyps or allergic rhinitis in a subject comprises a combination of an IL33 antagonist and an IL-4R antagonist. The subject has i) the intronic IL1RL1 variant rs1420101 or a variant in linkage disequilibrium thereof, and ii) the IL33 variant rs1342326 or a variant in linkage disequilibrium thereof.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present disclosure relates generally to the field of precision medicine. More specifically, the present disclosure relates to detection of risk alleles in genes encoding IL33 and IL1RL1 that can be used to stratify inflammatory lung disease patients at increased risk of developing one or more of the inflammatory lung disease conditions and their eosinophil subtypes. [Background technology]

[0002] Various publications, including patents, published applications, accession numbers, technical articles and journal articles, are cited throughout this specification. Each of these cited publications is incorporated by reference herein in its entirety for all purposes.

[0003] Asthma and chronic obstructive pulmonary disease (COPD) are highly prevalent obstructive lung diseases with substantial unmet clinical need and significant diagnostic overlap, which has led to growing interest in the intersection of these conditions, termed the asthma-COPD overlap syndrome (ACOS). There has been a long-standing controversy as to whether the two diseases have a common etiology (the so-called "Dutch hypothesis") or independent mechanistic causes (the so-called "British hypothesis"). Despite recent progress in elucidating the genetic contribution to shared multi-disease risk, including obstructive pulmonary disease, there are no well-established genetic findings linking asthma and COPD.

[0004] Genome-wide association studies (GWAS) have identified common genetic variants in interleukin-33 (IL33) and / or IL1RL1 that are associated with asthma. IL33 is a proinflammatory cytokine and a member of the interleukin-1 (IL-1) cytokine family that is expressed in a subset of cells in barrier tissues, including the lung epithelium. IL33 signals through a heterodimeric receptor complex composed of the IL33-specific receptor IL1RL1 (also known as ST2 or IL33R) and the co-receptor IL-1RAcP, which is common to several receptors in the IL-1 family.

[0005] In damaged tissues, originally sequestered IL33 is passively released by necrotic cells into the extracellular compartment and functions as an endogenous "danger signal" (alarmin) that activates inflammatory and repair pathways. Cigarette smoke induces IL33 expression in lung epithelial cells in mice, and IL33 expression is elevated in the bronchial epithelium of both asthma and COPD patients. In disease states where inflammatory infiltrates and inflammatory cytokines are already present, the pool of IL33-responsive cells increases, and IL33 signaling further amplifies the immune response, potentially leading to pathological inflammation and excessive immune responses that may cause chronic inflammatory diseases such as COPD.

[0006] Asthma-COPD overlap syndrome (ACOS) also exists, characterized by symptoms common to both asthma and COPD. Nonetheless, the ability to diagnose ACOS remains a clinical challenge, given the difficulty in distinguishing between asthma and COPD due to their overlapping shared features.

[0007] Treatment challenges for asthma, COPD, and ACOS also remain, as resistance to corticosteroids (the standard of care) is very common. Similarly, other treatments, such as IL-5 therapy, do not work well at all on the eosinophil subsets of asthma and COPD.

[0008] Thus, there remains a need in the art to differentiate between asthma, COPD, and ACOS, as well as to more accurately identify patients with the eosinophil subsets of these disorders. Proper diagnosis can better direct treatment regimens and improve patient outcomes. Summary of the Invention

[0009] In a first aspect of the disclosure, a method of treating or inhibiting eosinophilic asthma comprises administering an IL33 antagonist, or administering an IL33 antagonist and an IL-4R antagonist to a subject having one or more risk alleles associated with eosinophilic asthma in the intronic IL1RL1 variant rs1420101 (SEQ ID NO: 357) or a variant in linkage disequilibrium therewith, in the IL33 variant rs1342326 (SEQ ID NO: 358) or a variant in linkage disequilibrium therewith, or in both the intronic IL1RL1 variant rs1420101 (SEQ ID NO: 357) or a variant in linkage disequilibrium therewith and the IL33 variant rs1342326 (SEQ ID NO: 358) or a variant in linkage disequilibrium therewith. The administration of the IL33 antagonist and / or the IL-4R antagonist is such that eosinophilic asthma is treated or inhibited in the subject.

[0010] In a second aspect of the disclosure, a method of treating or inhibiting eosinophilic chronic obstructive pulmonary disease (COPD) comprises administering an IL33 antagonist, or administering an IL33 antagonist and an IL-4R antagonist, to a subject having one or more risk alleles associated with eosinophilic COPD in intronic IL1RL1 variant rs1420101 (SEQ ID NO: 357) or a variant in linkage disequilibrium therewith, in IL33 variant rs1342326 (SEQ ID NO: 358) or a variant in linkage disequilibrium therewith, or in both intronic IL1RL1 variant rs1420101 (SEQ ID NO: 357) or a variant in linkage disequilibrium therewith and IL33 variant rs1342326 (SEQ ID NO: 358) or a variant in linkage disequilibrium therewith. Administration of an IL33 antagonist and / or an IL-4R antagonist is such that eosinophilic COPD is treated or inhibited in the subject.

[0011] In a third aspect of the disclosure, a method of treating or inhibiting eosinophilic asthma-chronic obstructive pulmonary disease (COPD) overlap syndrome (ACOS) comprises administering an IL33 antagonist, or administering an IL33 antagonist and an IL-4R antagonist, to a subject having one or more risk alleles associated with eosinophilic asthma in intronic IL1RL1 variant rs1420101 (SEQ ID NO: 357) or a variant in linkage disequilibrium therewith, in IL33 variant rs1342326 (SEQ ID NO: 358) or a variant in linkage disequilibrium therewith, or in both intronic IL1RL1 variant rs1420101 (SEQ ID NO: 357) or a variant in linkage disequilibrium therewith and IL33 variant rs1342326 (SEQ ID NO: 358) or a variant in linkage disequilibrium therewith. Administration of an IL33 antagonist and / or an IL-4R antagonist is such that eosinophilic COPD is treated or inhibited in the subject.

[0012] In a fourth aspect of the disclosure, a method of treating or inhibiting nasal polyps comprises administering an IL33 antagonist, or administering an IL33 antagonist and an IL-4R antagonist to a subject having one or more risk alleles associated with nasal polyps in intronic IL1RL1 variant rs1420101 (SEQ ID NO: 357) or a variant in linkage disequilibrium therewith, in IL33 variant rs1342326 (SEQ ID NO: 358) or a variant in linkage disequilibrium therewith, or in both intronic IL1RL1 variant rs1420101 (SEQ ID NO: 357) or a variant in linkage disequilibrium therewith and IL33 variant rs1342326 (SEQ ID NO: 358) or a variant in linkage disequilibrium therewith. The administration of the IL33 antagonist and / or the IL-4R antagonist is such that nasal polyps are treated or inhibited in the subject.

[0013] In a fifth aspect of the present disclosure, a method for assessing a risk of developing eosinophilic asthma, eosinophilic chronic obstructive pulmonary disease (COPD), or eosinophilic asthma-COPD overlap syndrome (ACOS) comprises: (A) detecting in a sample obtained from the subject one or more risk alleles associated with eosinophilic asthma, eosinophilic COPD, or eosinophilic ACOS in intronic IL1RL1 variant rs1420101 (SEQ ID NO: 357) or a variant in linkage disequilibrium therewith, in IL33 variant rs1342326 (SEQ ID NO: 358) or a variant in linkage disequilibrium therewith, or in both intronic IL1RL1 variant rs1420101 (SEQ ID NO: 357) or a variant in linkage disequilibrium therewith and IL33 variant rs1342326 (SEQ ID NO: 358) or a variant in linkage disequilibrium therewith; (B)(i) assigning a risk score of 1 to the subject if the subject has a risk allele in the intronic IL1RL1 variant rs1420101 (SEQ ID NO: 357) in one of the chromosome 2 homologs, or a variant in linkage disequilibrium therewith, or a risk allele in the IL33 variant rs1342326 (SEQ ID NO: 358) in one of the chromosome 9 homologs, or a variant in linkage disequilibrium therewith; (B)(ii) assigning a risk score of 2 to the subject if the subject has a risk allele in the intronic IL1RL1 variant rs1420101 (SEQ ID NO: 357) in both chromosome 2 homologs or a variant in linkage disequilibrium therewith, if the subject has a risk allele in the IL33 variant rs1342326 (SEQ ID NO: 358) in both chromosome 9 homologs or a variant in linkage disequilibrium therewith, or if the subject has a risk allele in the intronic IL1RL1 variant rs1420101 (SEQ ID NO: 357) in one chromosome 2 homolog or a variant in linkage disequilibrium therewith and a risk allele in the IL33 variant rs1342326 (SEQ ID NO: 358) in one chromosome 9 homolog or a variant in linkage disequilibrium therewith; (B)(iii) assigning a risk score of 3 to the subject if the subject has a risk allele in the intronic IL1RL1 variant rs1420101 (SEQ ID NO: 357) in both chromosome 2 homologs, or a variant in linkage disequilibrium therewith, and a risk allele in the IL33 variant rs1342326 (SEQ ID NO: 358) in one of the chromosome 9 homologs, or a variant in linkage disequilibrium therewith, or if the subject has a risk allele in the intronic IL1RL1 variant rs1420101 (SEQ ID NO: 357) in one of the chromosome 2 homologs, or a variant in linkage disequilibrium therewith, and a risk allele in the IL33 variant rs1342326 (SEQ ID NO: 358) in both chromosome 9 homologs, or a variant in linkage disequilibrium therewith; or (B)(iv) if the subject has a risk allele in the intronic IL1RL1 variant rs1420101 (SEQ ID NO: 357) or a variant in linkage disequilibrium therewith in both chromosome 2 homologs and a risk allele in the IL33 variant rs1342326 (SEQ ID NO: 358) or a variant in linkage disequilibrium therewith in both chromosome 9 homologs, assigning the subject a risk score of 4; and (C) Classifying the subject's risk of developing eosinophilic asthma, eosinophilic COPD, or eosinophilic ACOS, where a risk score of 1 indicates that the subject is at risk of developing the high eosinophil subset of eosinophilic asthma, the high eosinophil subset of eosinophilic COPD, or the high eosinophil subset of eosinophilic ACOS, and a risk score of 2 indicates that the subject is at risk of developing the high eosinophil subset of eosinophilic asthma, the high eosinophil subset of eosinophilic COPD, or the high eosinophil subset of eosinophilic ACOS. a risk score of 1 indicates that the subject is at increased risk of developing eosinophil high subset of eosinophilic asthma, eosinophil high subset of eosinophilic COPD, or eosinophil high subset of eosinophilic ACOS, and a risk score of 2 indicates that the subject is at increased risk of developing eosinophil high subset of eosinophilic asthma, eosinophil high subset of eosinophilic COPD, or eosinophil high subset of eosinophilic ACOS, and a risk score of 3 indicates that the subject is at increased risk of developing eosinophil high subset of eosinophilic asthma, eosinophil high subset of eosinophilic COPD, or eosinophil high subset of eosinophilic ACOS. The method may further include treating or inhibiting one or more of eosinophilic asthma, eosinophilic COPD, or eosinophilic ACOS, including the eosinophil high subset of eosinophilic asthma, eosinophilic COPD, or eosinophil high subset of eosinophilic ACOS, in the subject by administering to the subject an IL33 antagonist or an IL33 antagonist and an IL-4R antagonist.

[0014] In a sixth aspect of the disclosure, an IL33 antagonist or a combination of an IL33 antagonist and an IL-4R antagonist is administered to a patient with eosinophilic asthma, eosinophilic chronic obstructive pulmonary disease (COPD), eosinophilic asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS), hypereosinophilic eosinophilic asthma, hypereosinophilic COPD, hypereosinophilic eosinophilic ACOS, or nasal polyps, in a patient with an IL1RL1 variant rs1420101 (SEQ ID NO: 357) or a variant in linkage disequilibrium therewith, in a patient with an IL33 variant rs1342326 (SEQ ID NO: 358) or a variant in linkage disequilibrium therewith, or in a patient with an IL1RL1 variant rs1420 101 (SEQ ID NO: 357) or a variant in linkage disequilibrium therewith, and IL33 variant rs1342326 (SEQ ID NO: 358) or a variant in linkage disequilibrium therewith, for use in treating or inhibiting any one of eosinophilic asthma, eosinophilic chronic obstructive pulmonary disease (COPD), eosinophilic asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS), hypereosinophilic eosinophilic asthma, hypereosinophilic COPD, hypereosinophilic eosinophilic ACOS, or nasal polyps, or for use in the manufacture of a medicament for treating or inhibiting the same, when a patient has one or more risk alleles associated with eosinophilic asthma, eosinophilic COPD, or eosinophilic ACOS in both IL33 variant rs1342326 (SEQ ID NO: 359) or a variant in linkage disequilibrium therewith.

[0015] According to any one of these aspects, the subject may have at least one risk allele associated with eosinophilic asthma in the intronic IL1RL1 variant rs1420101 (SEQ ID NO: 357) or a variant in linkage disequilibrium therewith, or may have two risk alleles associated with eosinophilic asthma in the intronic IL1RL1 variant rs1420101 (SEQ ID NO: 357) or a variant in linkage disequilibrium therewith, or may have at least one risk allele associated with eosinophilic asthma in the IL33 variant rs1342326 (SEQ ID NO: 358) or a variant in linkage disequilibrium therewith. may have an allele, or may have two risk alleles associated with eosinophilic asthma in IL33 variant rs1342326 (SEQ ID NO: 358) or a variant in linkage disequilibrium therewith, and may further have at least one risk allele associated with eosinophilic asthma in IL33 variant rs1342326 (SEQ ID NO: 358) or a variant in linkage disequilibrium therewith, and / or may further have two risk alleles associated with eosinophilic asthma in IL33 variant rs1342326 (SEQ ID NO: 358) or a variant in linkage disequilibrium therewith.

[0016] According to any one of these aspects, the method may comprise administering to the subject an IL33 antagonist, or the use may be for administering to the subject an IL33 antagonist, or the method may comprise administering to the subject an IL33 antagonist and an IL-4R antagonist, or the use may be for administering to the subject an IL33 antagonist and an IL-4R antagonist. The IL33 antagonist may comprise an antibody that specifically binds to IL33 trap or IL33. The IL-4R antagonist may comprise an antibody that specifically binds to IL-4R.

[0017] According to any of these embodiments, the IL33 trap may comprise a first IL33 binding domain comprising an IL33 binding portion of IL1RL1 and a second IL33 binding domain comprising an extracellular portion of IL-1RAcP. According to any of these embodiments, an antibody or antigen-binding fragment thereof that specifically binds to IL33 may comprise the H1, H2, and H3 domains of SEQ ID NO:274 and the L1, L2, and L3 domains of SEQ ID NO:282. According to any of these embodiments, an antibody or antigen-binding fragment thereof that specifically binds to IL-4R may comprise the H1, H2, and H3 domains of SEQ ID NO:337 and the L1, L2, and L3 domains of SEQ ID NO:338. [Brief description of the drawings]

[0018] [Figure 1]Panels A, B, C, and D show four exemplary configurations of the individual components of an IL33 antagonist in relation to each other. Panel A shows an arrangement in which a first IL33 binding domain (D1) is attached to the N-terminus of a first multimerization domain (M1) and a second IL33 binding domain (D2) is attached to the N-terminus of a second multimerization domain (M2). D1 is shown as an open box and D2 is shown as a closed box, indicating that D1 and D2 are derived from different IL33 binding proteins. Panel B shows an arrangement in which a first IL33 binding domain (D1) is attached to the N-terminus of a first multimerization domain (M1) and a second IL33 binding domain (D2) is attached to the C-terminus of a second multimerization domain (M2). D1 is shown as an open box and D2 is shown as a closed box, indicating that D1 and D2 are derived from different IL33 binding proteins. Panels C and D show configurations comprising four IL33 binding domains, namely D1, D2, D3 and D4. In these configurations, D3-D1-M1 and D4-D2-M2 are bound in a line, D3 is bound to the N-terminus of D1, D1 is bound to the N-terminus of M1, D4 is bound to the N-terminus of D2 and D2 is bound to the N-terminus of M2. In panel C, D3 and D4 are identical or substantially identical to each other, and D1 and D2 are identical or substantially identical to each other. In panel D, D1 and D4 are identical or substantially identical to each other, and D3 and D2 are identical or substantially identical to each other. [Figure 2-1] Panels A, B, C, and D show the association of rs1420101 (IL1RL1, also known as ST2), rs1342326 (IL33) and rs146597587 (IL33-pLoF) with (Panel A) eosinophil count (Panel B) log10 eosinophil count. The association of the total amount of rs1420101 and rs1342326 risk alleles with (Panel C) eosinophil count (Panel D) log10 eosinophil count is also shown. Effect sizes and P values ​​for eosinophil count and log10 eosinophil count were calculated using linear regression with adjustment for age, age2, sex, smoking status and ancestry principal components. P values ​​and effect size / odds ratios were estimated for individual scores, in each case compared to individuals without the risk allele. Additionally, the overall allele effect p value is shown. [Figure 2-2] Same as above. [Figure 2-3] Same as above. [Figure 2-4] Same as above. [Figure 3-1] Panels A, B, and C show the association of rs1420101 (IL1RL1, also known as ST2), rs1342326 (IL33), and rs146597587 (IL33-pLoF) with (Panel A) asthma, (Panel B) high eosinophil asthma subsets, and (Panel C) low eosinophil asthma subsets. Odds ratios for disease were calculated using logistic regression with adjustment for age, age2, sex, smoking status, and ancestry principal components. [Figure 3-2] Same as above. [Figure 3-3] Same as above. [Figure 4-1] Panels A, B, and C show the association of rs1420101 (IL1RL1, also known as ST2), rs1342326 (IL33), and rs146597587 (IL33-pLoF) with (Panel A) COPD, (Panel B) high eosinophil COPD subsets, and (Panel C) low eosinophil COPD subsets. Odds ratios for disease were calculated using logistic regression with adjustment for age, age2, sex, smoking status, and principal components of ancestry. [Figure 4-2] Same as above. [Figure 4-3] Same as above. [Figure 5-1] Panels A, B, and C show the association of rs1420101 (IL1RL1, also known as ST2), rs1342326 (IL33), and rs146597587 (IL33-pLoF) with (Panel A) ACOS, (Panel B) high eosinophil ACOS subset, and (Panel C) low eosinophil ACOS subset. Odds ratios for disease were calculated using logistic regression with adjustment for age, age2, sex, smoking status, and ancestry principal components. [Figure 5-2] Same as above. [Figure 5-3] Same as above. [Figure 6-1]Panels A, B, and C show the association of the genetic score (total amount of rs1420101 and rs1342326 risk alleles) with (Panel A) asthma (Panel B) COPD, and (Panel C) ACOS. P-value odds ratios were estimated for the individual scores, in each case compared with individuals without the risk allele. Additionally, an overall trend test p-value is shown. [Figure 6-2] Same as above. [Figure 6-3] Same as above. [Figure 7-1] Panels A, B, and C show the association of the genetic score (total amount of rs1420101 and rs1342326 risk alleles) with (Panel A) high and low eosinophil asthma (Panel B) high and low eosinophil COPD and (Panel C) high and low eosinophil ACOS. P-value odds ratios were estimated for the individual scores, in each case compared to individuals without the risk allele. Additionally, an overall trend test p-value is shown. [Figure 7-2] Same as above. [Figure 7-3] Same as above. [Figure 8-1] Panels A, B, C, and D show the clinical characteristics of study participants stratified by capture reagent (Panel A) VCRome and (Panel B) xGEN, and chip platform (Panel C) OMNI and (Panel D) GSA. [Figure 8-2] Same as above. [Figure 9-1] Panels A and B show the association of rs1420101 (IL1RL1, also known as ST2), rs1342326 (IL33), rs146597587 (IL33-pLoF) and gene score (sum of rs1420101 and rs1342326 risk alleles) with (Panel A) allergic rhinitis and (Panel B) nasal polyps. Odds ratios for disease were calculated using logistic regression with adjustment for age, age2, sex, smoking status and ancestry principal components. To test for the sum of common risk variants, P values ​​and odds ratios were estimated for the individual scores, in each case compared to individuals without the risk allele. Additionally, an overall trend test p value is shown. [Figure 9-2]Same as above. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0019] Various terms relating to aspects of the present disclosure are used throughout the specification and claims. Such terms are to be given their ordinary meanings in the art unless otherwise indicated. Other specifically defined terms are to be interpreted in a manner consistent with the definitions provided herein.

[0020] As used herein, the singular forms "a," "an," and "the" include plural referents unless the content clearly dictates otherwise. The terms "subject" and "patient" are used interchangeably and include any animal. Mammals are preferred, including companion animals (e.g., cats, dogs) and domesticated mammals (e.g., pigs, horses, cows), as well as rodents, including mice, rabbits, and rats, guinea pigs, and other rodents. Non-human primates are more preferred, and humans are highly preferred.

[0021] The term "isolated" means removed and / or altered by the hand of man from the natural environment. A "risk allele" includes alternative polymorphisms at a particular position that are associated with the risk of developing a disease, disorder, or condition.

[0022] "Linkage disequilibrium" refers to the nonrandom association of alleles at two or more loci. In accordance with the present disclosure, IL1R1 rs1420101 (SEQ ID NO: 357) and IL33 It has been observed that the single nucleotide polymorphism of rs1342326 (SEQ ID NO: 358) is associated with an increased risk of asthma, as well as the high eosinophil subset of asthma, COPD, and ACOS. In addition, it has been observed that individuals with higher doses of these risk alleles across both loci have a greater associated disease risk, and that heterozygous carriers of rare pLOF variants in IL33 have lower lifetime median eosinophil counts, a trend that reflects a reduced risk of asthma, as well as a trend that reflects a reduced risk of the high eosinophil subset of asthma, COPD, and ACOS. Genetic variants in the IL33 pathway have not previously been thought to be associated with COPD, and furthermore, it is believed that no genetic association between asthma and COPD or between the IL33 pathway and the risk of the high eosinophil subset of asthma, COPD, and ACOS has been reported. Furthermore, it was observed that the single nucleotide polymorphisms of IL1R1 rs1420101 and IL33 rs1342326, taken individually and collectively, are associated with an increased risk of nasal polyps and allergic rhinitis. These data indicate a role for blocking interleukin-33 in treating the hypereosinophilic forms of obstructive pulmonary diseases such as asthma, COPD, and ACOS, as well as other upper airway diseases such as nasal polyps and their hypereosinophilic subsets. Thus, the present disclosure features methods for identifying the risk of, diagnosing, treating, and inhibiting asthma, COPD, and ACOS, particularly their hypereosinophilic subsets.

[0023] In a first aspect, the disclosure features a method for assessing the risk of developing an inflammatory lung disease. The inflammatory lung disease can be one or more of asthma, COPD, ACOS, or nasal polyps. The asthma can be eosinophilic asthma or hypereosinophilic eosinophilic asthma. The COPD can be eosinophilic COPD or hypereosinophilic eosinophilic COPD. The ACOS can be eosinophilic ACOS or hypereosinophilic eosinophilic ACOS. In general, the method includes detecting one or more risk alleles associated with the risk of developing such an inflammatory lung disease.

[0024] In some embodiments, the method includes detecting one or more risk alleles associated with eosinophilic asthma, eosinophilic COPD, eosinophilic ACOS, or nasal polyps in a sample obtained from the subject, in an intronic IL1RL1 variant rs1420101 (SEQ ID NO: 357) or a variant in linkage disequilibrium therewith, in an IL33 variant rs1342326 (SEQ ID NO: 358) or a variant in linkage disequilibrium therewith, or in both an intronic IL1RL1 variant rs1420101 (SEQ ID NO: 357) or a variant in linkage disequilibrium therewith and an IL33 variant rs1342326 (SEQ ID NO: 358) or a variant in linkage disequilibrium therewith, and then detecting a risk allele in an intronic IL1RL1 variant rs1420101 (SEQ ID NO: 357) or a variant in linkage disequilibrium therewith in one of the chromosome 2 homologs or an IL33 variant rs1342326 (SEQ ID NO: 358) or a variant in linkage disequilibrium therewith in one of the chromosome 9 homologs, assigning a risk score of 1 to the subject if the subject has a risk allele in the intronic IL1RL1 variant rs1420101 (SEQ ID NO: 357) or a variant in linkage disequilibrium therewith in both chromosome 2 homologs; assigning a risk score of 2 to the subject if the subject has a risk allele in the IL33 variant rs1342326 (SEQ ID NO: 358) or a variant in linkage disequilibrium therewith in both chromosome 9 homologs; or assigning a risk score of 2 to the subject if the subject has a risk allele in the intronic IL1RL1 variant rs1420101 (SEQ ID NO: 357) or a variant in linkage disequilibrium therewith in one of the chromosome 2 homologs and a risk allele in the IL33 variant rs1342326 (SEQ ID NO: 358) or a variant in linkage disequilibrium therewith in one of the chromosome 9 homologs;If the subject has a risk allele in the intronic IL1RL1 variant rs1420101 (SEQ ID NO: 357) in one of the chromosome 2 homologs or a variant in linkage disequilibrium therewith and a risk allele in the IL33 variant rs1342326 (SEQ ID NO: 358) in one of the chromosome 9 homologs or a variant in linkage disequilibrium therewith, or if the subject has a risk allele in the intronic IL1RL1 variant rs1420101 (SEQ ID NO: 357) in one of the chromosome 2 homologs or a variant in linkage disequilibrium therewith and an IL3 or assigning a risk score of 3 to the subject if the subject has a risk allele in the intronic IL1RL1 variant rs1420101 (SEQ ID NO: 357) or a variant in linkage disequilibrium therewith in both chromosome 2 homologs and a risk allele in the IL33 variant rs1342326 (SEQ ID NO: 358) or a variant in linkage disequilibrium therewith in both chromosome 9 homologs.

[0025] In some embodiments, the risk allele of the IL33 variant rs1342326 comprises a single nucleotide polymorphism (SNP). In some detailed embodiments, the IL33 variant comprises SNP9:6190076:A:C (human genome GRCh38). The variant rs1342326 comprises the following nucleic acid sequence: CCAATCTTTTCTCATGAAGACACCA[G / T]CATGACCTCTTATTCTTATTTATAT (SEQ ID NO: 358).

[0026] In some embodiments, the risk allele of the IL1RL1 variant rs1420101 comprises a SNP. In some detailed embodiments, the IL1RL1 variant comprises SNP2:102341256:C:T (human genome GRCh38). The variant rs1420101 comprises the following nucleic acid sequence: TATACCATCACAAAGCCTCTCATTA[A / G]ACTTTGAATCCAATGAGTATTACTA (SEQ ID NO: 357).

[0027] Detection may be by any suitable technique: risk alleles may be detected, for example, by sequencing, genotyping, imputation, probing with complementary nucleic acid probes.

[0028] The method may further include classifying the subject's risk of developing eosinophilic asthma, eosinophilic COPD, or eosinophilic ACOS, where a risk score of 1 indicates that the subject is at risk of developing the high eosinophil subset of eosinophilic asthma, the high eosinophil subset of eosinophilic COPD, or the high eosinophil subset of eosinophilic ACOS, and a risk score of 2 indicates that the subject is at risk of developing the high eosinophil subset of eosinophilic asthma, the high eosinophil subset of eosinophilic COPD, or the high eosinophil subset of eosinophilic ACOS. A risk score of 3 indicates that the subject is at high risk of developing the high eosinophil subset of eosinophilic asthma, the high eosinophil subset of eosinophilic COPD, or the high eosinophil subset of eosinophilic ACOS, and a risk score of 4 indicates that the subject is at very high risk of developing the high eosinophil subset of eosinophilic asthma, the high eosinophil subset of eosinophilic COPD, or the high eosinophil subset of eosinophilic ACOS. On this scale, elevated risk is greater than risk but less than high risk, and very high risk is greater than high risk. Thus, in terms of the patient risk of developing the disease, risk<elevated risk<high ​​risk<very high risk, or risk score 1<risk score 2<risk score 3<risk score 4.

[0029] The method may further include obtaining a sample from the subject. Generally, the sample may include any sample from which a risk allele may be detected. The sample may include a tissue sample or sputum. The tissue sample may include peripheral blood, airway or lung tissue.

[0030] The method may further include identifying the subject as a candidate for treatment with an IL33 antagonist or a combination of an IL33 antagonist and an IL-4R antagonist. Based on the classification of the subject's risk as risk score 1, risk score 2, risk score 3, or risk score 4, the subject may benefit from a treatment regimen that inhibits eosinophilic asthma, eosinophilic COPD, eosinophilic ACOS, or high eosinophil subsets thereof, or nasal polyps. The inhibitory treatment regimen may include adjustments to the type, dose, frequency of administration, etc. of the IL33 antagonist, as well as whether or not it is combined with an IL-4R antagonist, and if so, the type, dose, and frequency of administration, etc. of the IL-4R antagonist depending on, for example, the level of risk.

[0031] The method can further comprise detecting the increased level of eosinophil count from the blood or sputum separated from the subject.The increased level is considered to be above normal level or above the level normally observed in the subjects with asthma, COPD or ACOS non-eosinophil subset.The method can further comprise isolating blood or sputum from the subject for this purpose.

[0032] The method may further comprise administering to the subject an IL33 antagonist, or an IL33 antagonist and an IL-4R antagonist. Such administration may be in an amount effective to inhibit eosinophilic asthma, eosinophilic COPD, or eosinophilic ACOS, or high eosinophil subsets thereof. In some embodiments, the IL33 antagonist may comprise an IL33 trap. In some embodiments, the IL33 antagonist may comprise an antibody or antigen-binding fragment thereof that specifically binds to IL33. Suitable IL33 antagonists are described herein. In some embodiments, the IL-4R antagonist may comprise an antibody or antigen-binding fragment thereof that specifically binds to IL-4R. Suitable IL-4R antagonists are described herein.

[0033] In a second aspect, the present disclosure features a method for treating or inhibiting eosinophilic asthma in a subject in need of such treatment or inhibition.The eosinophilic asthma can be a low eosinophil subset of eosinophilic asthma or a high eosinophil subset of eosinophilic asthma.

[0034] In some embodiments, the method comprises administering an IL33 antagonist to a subject having one or more risk alleles associated with eosinophilic asthma in intronic IL1RL1 variant rs1420101 (SEQ ID NO: 357) or a variant in linkage disequilibrium therewith, in IL33 variant rs1342326 (SEQ ID NO: 358) or a variant in linkage disequilibrium therewith, or in both intronic IL1RL1 variant rs1420101 (SEQ ID NO: 357) or a variant in linkage disequilibrium therewith and IL33 variant rs1342326 (SEQ ID NO: 358) or a variant in linkage disequilibrium therewith, or administering an IL33 antagonist and an IL-4R antagonist, wherein eosinophilic asthma is treated or inhibited in the subject.

[0035] In some embodiments, the IL33 antagonist may comprise an IL33 trap. In some embodiments, the IL33 antagonist may comprise an antibody or antigen-binding fragment thereof that specifically binds to IL33. Suitable IL33 antagonists are described herein. In some embodiments, the IL-4R antagonist may comprise an antibody or antigen-binding fragment thereof that specifically binds to IL-4R. Suitable IL-4R antagonists are described herein.

[0036] In a third aspect, the disclosure features a method of treating or inhibiting eosinophilic COPD in a subject in need thereof, the eosinophilic COPD can be a low eosinophil subset of eosinophilic COPD or a high eosinophil subset of eosinophilic COPD.

[0037] In some embodiments, the method comprises administering an IL33 antagonist to a subject having one or more risk alleles associated with eosinophilic COPD in intronic IL1RL1 variant rs1420101 (SEQ ID NO: 357) or a variant in linkage disequilibrium therewith, in IL33 variant rs1342326 (SEQ ID NO: 358) or a variant in linkage disequilibrium therewith, or in both intronic IL1RL1 variant rs1420101 (SEQ ID NO: 357) or a variant in linkage disequilibrium therewith and IL33 variant rs1342326 (SEQ ID NO: 358) or a variant in linkage disequilibrium therewith, or administering an IL33 antagonist and an IL-4R antagonist, wherein eosinophilic COPD is treated or inhibited in the subject.

[0038] In some embodiments, the IL33 antagonist may comprise an IL33 trap. In some embodiments, the IL33 antagonist may comprise an antibody or antigen-binding fragment thereof that specifically binds to IL33. Suitable IL33 antagonists are described herein. In some embodiments, the IL-4R antagonist may comprise an antibody or antigen-binding fragment thereof that specifically binds to IL-4R. Suitable IL-4R antagonists are described herein.

[0039] In a fourth aspect, the disclosure features a method for treating or inhibiting eosinophilic ACOS in a subject in need of such treatment or inhibition. The eosinophilic ACOS can be a low eosinophil subset of eosinophilic ACOS or a high eosinophil subset of eosinophilic ACOS.

[0040] In some embodiments, the method comprises administering an IL33 antagonist to a subject having one or more risk alleles associated with eosinophilic ACOS in intronic IL1RL1 variant rs1420101 (SEQ ID NO: 357) or a variant in linkage disequilibrium therewith, in IL33 variant rs1342326 (SEQ ID NO: 358) or a variant in linkage disequilibrium therewith, or in both intronic IL1RL1 variant rs1420101 (SEQ ID NO: 357) or a variant in linkage disequilibrium therewith and IL33 variant rs1342326 (SEQ ID NO: 358) or a variant in linkage disequilibrium therewith, or administering an IL33 antagonist and an IL-4R antagonist, wherein eosinophilic ACOS is treated or inhibited in the subject.

[0041] In some embodiments, the IL33 antagonist may comprise an IL33 trap. In some embodiments, the IL33 antagonist may comprise an antibody or antigen-binding fragment thereof that specifically binds to IL33. Suitable IL33 antagonists are described herein. In some embodiments, the IL-4R antagonist may comprise an antibody or antigen-binding fragment thereof that specifically binds to IL-4R. Suitable IL-4R antagonists are described herein.

[0042] In any of the methods described or exemplified herein, an IL33 antagonist may be administered as part of a treatment regimen. An IL33 antagonist may include any agent that inhibits the interaction of IL33 with one or more of its binding partners, thereby inhibiting IL33-mediated signal transduction. For example, an IL33 antagonist may bind to IL33 and / or interact with IL33, or with the IL33 receptor termed "suppression of tumorigenicity" (also known as ST2), or with the IL33 coreceptor interleukin-1 receptor accessory protein (IL-1RAcP), or with any of the following complexes: IL33 / ST2, or ST2 / IL-1RAcP.

[0043] Non-limiting examples of categories of IL33 antagonists include small molecule IL33 inhibitors, or receptor antagonists, or nucleic acids that hybridize under stringent conditions to nucleic acid sequences encoding either IL33, or the IL33 receptor or co-receptor (e.g., short interfering RNA (siRNA) or clustered regularly interspaced short palindromic repeats RNA (CRISPR-RNA or crRNA), including single guide RNA (sgRNA) with crRNA and tracrRNA sequences). Other IL33 antagonists include ligand-binding portions of the IL33 receptor (e.g., ST2), IL33-binding scaffold molecules (e.g., DARPins, HEAT repeat proteins, ARM repeat proteins, tetratricopeptide repeat proteins, fibronectin-based scaffold constructs, and other scaffolds based on naturally occurring repeat proteins), and proteins that include anti-IL33 aptamers or portions thereof.

[0044] In a preferred embodiment, the IL33 antagonist comprises an antibody that specifically binds to human IL33 (IL33 antibody), or an antigen-binding fragment thereof. The amino acid sequence identifiers of exemplary anti-IL33 antibodies for use in the methods described herein are shown in Table 1. The anti-IL33 antibody may include any of the antibodies described in U.S. Patent No. 9,453,072, which is incorporated by reference in its entirety.

[0045] [Table 1]

[0046] In some embodiments, the IL33 antagonist comprises an anti-IL33 antibody, or an antigen-binding fragment thereof, comprising a heavy chain variable region (HCVR), a light chain variable region (LCVR), and / or a complementarity determining region (CDR) of an amino acid sequence of an anti-IL33 antibody as described in U.S. Pat. No. 9,453,072 and in Table 1 herein. In some embodiments, the IL33 antagonist comprises a heavy chain complementarity determining region (CDR, e.g., H1, H2, H3) of a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:274 and a light chain CDR (e.g., L1, L2, L3) of a light chain variable region comprising the amino acid sequence of SEQ ID NO:282. In some embodiments, H1 comprises the amino acid sequence of SEQ ID NO:276, H2 comprises the amino acid sequence of SEQ ID NO:278, and H3 comprises the amino acid sequence of SEQ ID NO:280. In some embodiments, L1 comprises the amino acid sequence of SEQ ID NO: 284, L2 comprises the amino acid sequence of SEQ ID NO: 286, and L3 comprises the amino acid sequence of SEQ ID NO: 288. In still other embodiments, the anti-IL33 antibody or antigen-binding fragment thereof comprises a HCVR comprising SEQ ID NO: 274 and a LCVR comprising SEQ ID NO: 282.

[0047] In some embodiments, the IL33 antibody or antigen-binding fragment thereof comprises three heavy chain CDRs (HCDR1, HCDR2 and HCDR3) contained within a heavy chain variable region (HCVR) amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 18, 34, 50, 66, 82, 98, 114, 130, 146, 162, 178, 194, 210, 226, 242, 258, 274, 290, and 308, and three light chain CDRs (LCDR1, LCDR2 and LCDR3) contained within a light chain variable region (LCVR) amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 26, 42, 58, 74, 90, 106, 122, 138, 154, 170, 186, 202, 218, 234, 250, 266, 282, 298, and 316.

[0048] In some embodiments, the anti-IL33 antibody, or antigen-binding fragment thereof, comprises the HCVR and LCVR (HCVR / LCVR) sequence pair of SEQ ID NOs: 2 / 10, 18 / 26, 34 / 42, 50 / 58, 66 / 74, 82 / 90, 98 / 106, 114 / 122, 130 / 138, 146 / 154, 162 / 170, 178 / 186, 194 / 202, 210 / 218, 226 / 234, 242 / 250, 258 / 266, 274 / 282, 290 / 298, or 308 / 316.

[0049] In some embodiments, the anti-IL33 antibody, or antigen-binding fragment thereof, comprises a heavy chain CDR1 (HCDR1) domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 20, 36, 52, 68, 84, 100, 116, 132, 148, 164, 180, 196, 212, 228, 244, 260, 276, 292, and 310, or at least 90%, at least 95%, at least 98%, or at least 99% of the ... A heavy chain CDR2 (HCDR2) domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 6, 22, 38, 54, 70, 86, 102, 118, 134, 150, 166, 182, 198, 214, 230, 246, 262, 278, 294, and 312, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity thereto. and a light chain CDR1 (LCDR1) domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 12, 28, 44, 60, 76, 92, 108, 124, 140, 156, 172, 188, 204, 220, 236, 252, 268, 284, 300, and 318, or a substantially similar thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity thereto. and a light chain CDR2 (LCDR2) domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 14, 30, 46, 62, 78, 94, 110, 126, 142, 158, 174, 190, 206, 222, 238, 254, 270, 286, 302, and 320, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity.

[0050] In some preferred embodiments, the anti-IL33 antibody or antigen-binding fragment thereof has HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3 domains set forth in SEQ ID NOs: 4-6-8-12-14-16 (e.g., H1M9559N), 20-22-24-28-30-32 (e.g., H1M9566N), 36-38-40-44-46-48 (e.g., H1M9568N), 52-54-56-60-62-64 (e.g., H4H9629N), 60-62-64-66 (e.g., H4H9629N), 70-72-76-78 (e.g., H4H9629N), 80-82-84-86-88 (e.g., H4H9629N), 90-92-96-98-99 (e.g., H4H9629N), 100-102-112-12-13-14-15 (e.g., H4H9629N), 110-112-132-14-16 (e.g., H4H9629N), 120-122-132-14-16 (e.g., H4H9559N), 130-132-14-17 (e.g., H4H9566N), 140-142-152-162-17 (e.g., H4H9566N), 150-152-162-17 (e.g., H4H9566N), 160-162-17 (e.g. P), 68-70-72-76-78-80 (e.g., H4H9633P), 84-86-88-92-94-96 (e.g., H4H9640P), 100-102-104-108-110-112 (e.g., H4H9659P), 116-118-120-124-126-128 (e.g., H4H9660P), 132-134-136-140-142-144 (e.g., H4H9662P), 148-150-152-156-158-160 (e.g., , H4H9663P), 164-166-168-172-174-176 (e.g., H4H9664P), 180-182-184-188-190-192 (e.g., H4H9665P), 196-198-200-204-206-208 (e.g., H4H9666P), 212-214-216-220-222-224 (e.g., H4H9667P), 228-230-232-236-238-240 (e.g., H4H9670P), 244-246 -248-252-254-256 (e.g., H4H9671P), 260-262-264-268-270-272 (e.g., H4H9672P), 276-278-280-284-286-288 (e.g., H4H9675P), 292-294-296-300-302-304 (e.g., H4H9676P), and 310-312-314-318-320-322 (H1M9565N).

[0051] In some embodiments, an anti-IL33 antibody, or antigen-binding fragment thereof, comprises heavy and light chain CDR domains contained within the heavy and light chain variable region (HCVR / LCVR) sequences of SEQ ID NOs: 2 / 10, 18 / 26, 34 / 42, 50 / 58, 66 / 74, 82 / 90, 98 / 106, 114 / 122, 130 / 138, 146 / 154, 162 / 170, 178 / 186, 194 / 202, 210 / 218, 226 / 234, 242 / 250, 258 / 266, 274 / 282, 290 / 298, or 308 / 316. CDR boundaries may be according to the Kabat, Chothia, or AbM definitions.

[0052] Other anti-IL33 antibodies and antigen-binding fragments thereof that may be used in the methods described herein are disclosed in European Publication No. EP1725261, PCT Publication No. WO2011 / 031600, PCT Publication No. WO2015 / 099175, PCT Publication No. WO2015 / 106080 (ANB020), PCT Publication No. WO2016 / 077381, PCT Publication No. WO2016 / 077366, or PCT Publication No. WO2016 / 156440, U.S. Patent No. 8,187,596, and U.S. Publication No. 2016 / 0168242, each of which is incorporated herein by reference in its entirety.

[0053] In an alternative preferred embodiment, the IL33 antagonist comprises an IL33 trap. The IL33 trap comprises at least one IL33 binding domain, which comprises the IL33 binding portion of the IL33 receptor protein, termed ST2. In some embodiments, the IL33 trap further comprises the extracellular portion of the IL33 co-receptor, termed IL-1 receptor accessory protein, or IL-1RAcP. The IL33 trap may also comprise at least one multimerization component, which functions to bind the various components of the trap to each other. The various components of the IL33 trap are described below and illustrated in FIG. 1. The IL33 trap may comprise any of the traps described in U.S. Publication No. 2014 / 0271642 and PCT Publication No. WO2014 / 152195, each of which is incorporated herein by reference in its entirety.

[0054] An IL33 trap may comprise a first IL33 binding domain (D1) linked to a multimerization domain (M). In some embodiments, an IL33 trap comprises a second IL33 binding domain (D2) linked to D1 and / or M. In some preferred embodiments, D1 comprises the IL33 binding portion of the ST2 protein. In some preferred embodiments, D2 comprises the extracellular portion of the IL-1RAcP protein.

[0055] The individual components of the IL33 Trap may be arranged relative to one another in a variety of ways to provide a functional antagonist molecule capable of binding IL33. For example, D1 and / or D2 may be attached to the N-terminus of M. In some embodiments, D1 and / or D2 are attached to the C-terminus of M. In other embodiments, D1 is attached to the N-terminus of D2 and D2 is attached to the N-terminus of M, resulting in an N- to C-terminal in-line fusion of the antagonist molecule of the formula D1-D2-M. Other arrangements for the individual components are disclosed in FIG. 1 and elsewhere herein.

[0056] The IL33 trap comprises at least one IL33 binding domain (sometimes referred to herein as "D", or "D1", "D2", etc.). In some embodiments, the IL33 binding domain comprises an IL33 binding portion of an ST2 protein. The IL33 binding portion of an ST2 protein may comprise or consist of all or a portion of the extracellular domain of an ST2 protein. In preferred embodiments, the ST2 protein is a human ST2 protein, comprising amino acids 1-556 (SEQ ID NO: 352) of the ST2 protein of Accession No. NP_057316.3. In some alternative embodiments, the ST2 protein comprises an ST2 protein derived from a non-human species (e.g., mouse ST2, non-human primate ST2, etc.). A preferred IL33 binding portion of an ST2 protein is described herein as the amino acid sequence of SEQ ID NO: 328 (corresponding to the extracellular domain of human ST2 [K19-S328 of NCBI Accession No. NP_057316.3]). Another example of an IL33-binding portion of the ST2 protein is described herein as the amino acid sequence of SEQ ID NO:329 (corresponding to the extracellular domain of mouse ST2 [S27-R332 of NCBI Accession No. P14719]).

[0057] In some embodiments, the IL33 binding domain of the trap comprises an extracellular portion of an IL-1RAcP protein. In certain embodiments, the IL-1RAcP protein comprises a human IL-1RAcP protein, including an IL-1RAcP protein having an amino acid sequence of SEQ ID NO:353. In some alternative embodiments, the IL-1RAcP protein comprises an IL-1RAcP protein derived from a non-human species (e.g., mouse IL-1RAcP, non-human primate IL-1RAcP, etc.). An exemplary extracellular portion of an IL-1RAcP protein is described herein as the amino acid sequence of SEQ ID NO:330 (corresponding to the extracellular domain of human IL-1RAcP [S21-E359 of NCBI Accession No. Q9NPH3]). Another example of an extracellular portion of an IL-1RAcP protein is described herein as the amino acid sequence of SEQ ID NO:331 (corresponding to the extracellular domain of mouse IL-1RAcP [S21-E359 of NCBI Accession No. Q61730]).

[0058] Non-limiting examples of IL33 traps for use in the present methods are shown in Table 2 and include IL33 traps designated "hST2-hFC", "hST2-mFc", "hST2-hIL1RAcP-mFc", "hST2-hIL1RAcP-hFc" and "mST2-mIL1RAcP-mFc", which correspond to SEQ ID NOs: 323, 324, 325, 326 and 327, respectively. The IL33 receptor-based trap may comprise an amino acid sequence that is at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any of the exemplary IL33 receptor-based traps described herein (e.g., SEQ ID NOs: 323, 324, 325, 326 and 327). An IL33 trap may comprise a D1 and / or D2 component having an amino acid sequence that is at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any of the amino acid sequences of the exemplary IL33 binding domain components described herein (e.g., SEQ ID NOs:328, 329, 330 and 331).

[0059] Five different exemplary IL33 traps were constructed. The first IL33 antagonist (hST2-hFc, SEQ ID NO: 323) comprises the soluble extracellular domain of human ST2 (SEQ ID NO: 328) fused at its C-terminus to the N-terminus of a human IgG1 Fc domain (SEQ ID NO: 332). The second IL33 antagonist (hST2-mFc, SEQ ID NO: 324) consists of the soluble extracellular domain of human ST2 (SEQ ID NO: 328) fused at its C-terminus to the N-terminus of a mouse IgG2a Fc domain (SEQ ID NO: 333). The third IL33 antagonist (hST2-hIL1RAcP-mFc, SEQ ID NO:325) consists of an in-line fusion with human ST2 (SEQ ID NO:328) at its N-terminus, followed by the extracellular domain of human IL-1RAcP (SEQ ID NO:330) followed by mouse IgG2aFc (SEQ ID NO:333) at its C-terminus. The fourth IL33 antagonist (mST2-mIL1RAcP-mFc, SEQ ID NO:326) consists of an in-line fusion with mouse ST2 (SEQ ID NO:329) at its N-terminus, followed by the extracellular domain of mouse IL-1RAcP (SEQ ID NO:331) followed by mouse IgG2aFc (SEQ ID NO:333) at its C-terminus. The fifth IL33 antagonist (hST2-hIL1RAcP-hFc, SEQ ID NO:327) consists of an in-line fusion of human ST2, SEQ ID NO:328, at its N-terminus, followed by the extracellular domain of human IL-1RAcP (SEQ ID NO:330), followed by human IgG1Fc (SEQ ID NO:332) at its C-terminus. See Table 2.

[0060] [Table 2]

[0061] The IL33 trap may comprise at least one multimerization domain (sometimes referred to herein by the abbreviations "M", "M1", "M2", etc.). Broadly speaking, the multimerization domain(s) function to link the various components of the IL33 antagonist (e.g., the IL33 binding domain(s)) to one another. The multimerization domain may comprise any macromolecule that has the ability to associate (covalently or non-covalently) with a second macromolecule of the same or similar structure or composition. For example, the multimerization domain may comprise a polypeptide comprising an immunoglobulin CH3 domain. A non-limiting example of a multimerization domain is the Fc portion of an immunoglobulin, e.g., the Fc domain of an IgG selected from the isotypes IgG1, IgG2, IgG3, and IgG4, as well as any allotype within each isotype group.

[0062] Non-limiting exemplary multimerization domains that may be used in an IL33 Trap include human IgG1Fc (SEQ ID NO: 332) or mouse IgG2aFc (SEQ ID NO: 333). An IL33 Trap may include an M component having an amino acid sequence that is at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any of the amino acid sequences of the exemplary M components described herein (e.g., SEQ ID NO: 332 or 333).

[0063] In some embodiments, the IL33 trap comprises two multimerization domains, namely M1 and M2, where M1 and M2 are identical to each other. For example, M1 can be an Fc domain with a particular amino acid sequence, and M2 is an Fc domain with the same amino acid sequence as M1. The individual components of the IL33 antagonist (e.g., D1, D2, M, etc.) can be arranged in relation to each other in various ways. Non-limiting examples of all the above arrangements are illustrated diagrammatically in FIG. 1, including an example of an IL33 trap comprising two multimerization domains (M1 and M2) and four IL33 binding domains (D1, D2, D3, and D4).

[0064] The individual components of the IL33 trap (e.g., D1, D2, M1, M2, etc.) may be directly linked to each other (e.g., D1 and / or D2 may be directly linked to M, etc.) or the individual components may be linked to each other via a linker component (e.g., D1 and / or D2 may be linked to M via a linker oriented between the individual components, D1 may be linked to D2 via a linker, etc.).

[0065] Polypeptides that bind to IL33 and / or its receptors (ST2 and / or IL-1RAcP) and block the ligand-receptor interaction are considered IL33 antagonists, and are disclosed in PCT Publication No. WO2014 / 152195, which is incorporated by reference in its entirety. The biological characteristics of IL33 Trap are described in U.S. Publication No. 2014 / 0271642, which is incorporated by reference herein in its entirety.

[0066] Other agents that may act as IL33 antagonists and may be used in the present methods include immunoadhesins, peptibodies, and soluble ST2, or derivatives thereof, anti-IL33 receptor antibodies (e.g., anti-ST2 antibodies, such as AMG-282 (Amgen) or STLM15 (Janssen), or any of the anti-ST2 antibodies) described in PCT Publication Nos. WO2012 / 113813, WO2013 / 173761, and WO2013 / 165894, as well as U.S. Pat. Nos. 8,444,987 and 7,452,980, each of which is incorporated herein by reference in its entirety. Other IL33 antagonists include ST2-Fc proteins, such as those described in PCT Publication Nos. WO2013 / 173761 and WO2013 / 165894, each of which is incorporated by reference in its entirety.

[0067] In any of the methods described or exemplified herein, an IL-4R antagonist may be administered as part of a treatment regimen. The IL-4R antagonist is preferably administered in combination with an IL33 antagonist, but the IL-4R antagonist need not be administered simultaneously with the IL33 antagonist. The IL-4R antagonist may include any agent that binds to or interacts with IL-4Rα or an IL-4R ligand and inhibits or attenuates the normal biological signaling function of type 1 and / or type 2 IL-4 receptors. The IL-4R may comprise the amino acid sequence of SEQ ID NO:347, or a biologically active fragment thereof. The type 1 IL-4 receptor is a dimeric receptor consisting of an IL-4Rα chain and a γc chain. The type 2 IL-4 receptor is a dimeric receptor consisting of an IL-4Rα chain and an IL-13Rα1 chain. Type 1 IL-4 receptor interacts with and is stimulated by IL-4, whereas type 2 IL-4 receptor interacts with and is stimulated by both IL-4 and IL-13. Thus, the IL-4R antagonist used in the present methods may function by blocking IL-4-mediated signaling, IL-13-mediated signaling, or both IL-4- and IL-13-mediated signaling. Thus, the IL-4R antagonist may inhibit or prevent the interaction of IL-4 and / or IL-13 with the type 1 or type 2 receptor.

[0068] Non-limiting examples of categories of IL-4R antagonists include small molecule IL-4R antagonists, nucleic acid-based inhibitors of IL-4R expression or activity (e.g., siRNA or antisense), peptide-based molecules that specifically interact with IL-4R (e.g., peptibodies), "receptor bodies" (e.g., engineered molecules that contain the ligand-binding domain of an IL-4R component), IL-4R-binding scaffold molecules (e.g., DARPins, HEAT repeat proteins, ARM repeat proteins, tetratricopeptide repeat proteins, fibronectin-based scaffold constructs, and other scaffolds based on naturally occurring repeat proteins), and anti-IL-4R aptamers or portions thereof.

[0069] In a preferred embodiment, the IL-4R antagonist comprises an antibody that specifically binds to human IL-4R. Antibodies are generally referred to herein by the following nomenclature: an Fc prefix (e.g., "H1M" or "H4H") followed by a numerical identifier (e.g., "9559", "9566", or "9629" as shown in Table 1), followed by a "P" or "N" suffix. According to this nomenclature, antibodies may be referred to herein, for example, as "H1M9559N", "H1M9566N", "H4H9629P", etc. The H1M and H4H prefixes of the antibody name used herein indicate the particular Fc region isotype of the antibody. For example, an "H1M" antibody has a murine IgG1 Fc, whereas an "H4H" antibody has a human IgG4 Fc. While an antibody having a particular Fc isotype may be converted to an antibody having a different Fc isotype (e.g., an antibody having a murine IgG1 Fc may be converted to an antibody having a human IgG4 Fc, etc.), in any event, the variable domains (including the CDRs) as indicated by the numerical identifiers shown in Table 1 will remain the same, and regardless of the nature of the Fc, the binding characteristics are expected to be the same or substantially similar.

[0070] In a preferred embodiment, the anti-IL-4R antibody is dupilumab. See U.S. Patent Nos. 7,605,237, 7,608,693, and 9,290,574, which are incorporated by reference.

[0071] Human anti-IL-4R antibodies can be generated as described in U.S. Patent No. 7,608,693. One exemplary IL-4R antibody is a murine antibody specific for murine IL-4R and has the following amino acid sequences: a heavy chain variable region (HCVR) comprising SEQ ID NO: 335 and a light chain variable domain (LCVR) comprising SEQ ID NO: 336. A human anti-IL-4R antibody, designated dupilumab, specifically binds human IL-4Rα and comprises a heavy chain variable region (HCVR) comprising SEQ ID NO: 337 and a light chain variable region (LCVR) comprising SEQ ID NO: 338, a heavy chain complementarity determining region 1 (HCDR1) comprising SEQ ID NO: 339, an HCDR2 comprising SEQ ID NO: 340, an HCDR3 comprising SEQ ID NO: 341, a light chain complementarity determining region 1 (LCDR1) comprising SEQ ID NO: 342, an LCDR2 comprising SEQ ID NO: 343, and an LCDR3 comprising SEQ ID NO: 344. The full-length heavy chain of dupilumab is set forth as SEQ ID NO:345, and the full-length light chain is set forth as SEQ ID NO:346.

[0072] In some embodiments, the IL-4R antagonist comprises an anti-IL-4Rα antibody, or an antigen-binding fragment thereof, comprising a heavy chain variable region (HCVR), a light chain variable region (LCVR), and / or a complementarity determining region (CDR) comprising any of the amino acid sequences of the anti-IL-4R antibodies as described in U.S. Pat. Nos. 7,605,237 and 7,608,693. In some embodiments, the IL-4R antagonist comprises an anti-IL-4R antibody having the binding characteristics of a reference antibody referred to herein as dupilumab (U.S. Pat. Nos. 7,605,237 and 7,608,693). In some embodiments, the anti-IL-4Rα antibody, or an antigen-binding fragment thereof, comprises a heavy chain complementarity determining region (HCDR) of the heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO:337 and a light chain complementarity determining region (LCDR) of the light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO:338. In some embodiments, the anti-IL-4Rα antibody or antigen-binding fragment thereof comprises three HCDRs (HCDR1, HCDR2, and HCDR3) and three LCDRs (LCDR1, LCDR2, and LCDR3), where HCDR1 comprises the amino acid sequence of SEQ ID NO: 339, HCDR2 comprises the amino acid sequence of SEQ ID NO: 340, HCDR3 comprises the amino acid sequence of SEQ ID NO: 341, LCDR1 comprises the amino acid sequence of SEQ ID NO: 342, LCDR2 comprises the amino acid sequence of SEQ ID NO: 343, and LCDR3 comprises the amino acid sequence of SEQ ID NO: 344. In yet other embodiments, the anti-IL-4R antibody or antigen-binding fragment thereof comprises a HCVR comprising SEQ ID NO: 337 and a LCVR comprising SEQ ID NO: 338. In yet other embodiments, the anti-IL-4R antibody or antigen-binding fragment thereof comprises a HCVR comprising SEQ ID NO: 335 and a LCVR comprising SEQ ID NO: 336. In some embodiments, the anti-IL-4R antibody or antigen-binding fragment thereof comprises a heavy chain (HC) amino acid sequence as set forth in SEQ ID NO:345 and a light chain (LC) amino acid sequence as set forth in SEQ ID NO:346.

[0073] In some embodiments, the IL-4R antibody or antigen-binding fragment thereof comprises a heavy chain complementarity determining region (HCDR) of the heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO:335 or SEQ ID NO:337 and a light chain complementarity determining region (LCDR) of the light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO:336 or SEQ ID NO:338.

[0074] In some embodiments, an IL-4R antibody or antigen-binding fragment thereof comprises three HCDRs (HCDR1, HCDR2 and HCDR3) and three LCDRs (LCDR1, LCDR2 and LCDR3), wherein HCDR1 comprises the amino acid sequence of SEQ ID NO: 339, HCDR2 comprises the amino acid sequence of SEQ ID NO: 340, HCDR3 comprises the amino acid sequence of SEQ ID NO: 341, LCDR1 comprises the amino acid sequence of SEQ ID NO: 342, LCDR2 comprises the amino acid sequence of SEQ ID NO: 343 and LCDR3 comprises the amino acid sequence of SEQ ID NO: 344.

[0075] In some embodiments, an IL-4R antibody or antigen-binding fragment thereof for use in the methods of the disclosure comprises a HCVR comprising the amino acid sequence of SEQ ID NO:335 or SEQ ID NO:337 and a LCVR comprising the amino acid sequence of SEQ ID NO:336 or SEQ ID NO:338.

[0076] In some embodiments, the IL-4R antibody or antigen-binding fragment thereof for use in the methods of the disclosure comprises the HCVR / LCVR amino acid sequence pair of SEQ ID NO:335 / 336 or SEQ ID NO:337 / 338.

[0077] Other anti-IL-4Rα antibodies include, for example, the antibody designated and known in the art as AMG317 (Corren et al., 2010, Am J Respir Crit Care Med., 181(8):788-796), or MEDI9314, or any of the anti-IL-4Rα antibodies as described in any of U.S. Pat. Nos. 7,186,809, 7,605,237, 7,638,606, 8,092,804, 8,679,487, or 8,877,189.

[0078] Anti-IL-4Rα and IL33 antibodies may have pH-dependent binding properties. For example, anti-IL-4Rα or anti-IL33 antibodies may exhibit decreased binding to IL-4Rα or IL33, respectively, at acidic pH compared to neutral pH. Alternatively, anti-IL-4Rα or anti-IL33 antibodies may exhibit enhanced binding to their antigens at acidic pH compared to neutral pH. "Acidic pH" includes pH values ​​less than about 6.2, such as about 6.0, 5.95, 5.9, 5.85, 5.8, 5.75, 5.7, 5.65, 5.6, 5.55, 5.5, 5.45, 5.4, 5.35, 5.3, 5.25, 5.2, 5.15, 5.1, 5.05, 5.0, or less. "Neutral pH" includes a pH of about 7.0 to about 7.4, as well as about 7.0, 7.05, 7.1, 7.15, 7.2, 7.25, 7.3, 7.35, and 7.4.

[0079] In another embodiment, the IL33 antagonist is used alone or in combination with the IL-4R antagonist to treat or inhibit pulmonary inflammatory conditions. The IL33 antagonist or combination may be used to treat or inhibit one or more of asthma, COPD, or ACOS. The IL33 antagonist or combination may be used to treat or inhibit nasal polyps. The combination may be used to treat or inhibit one or more of eosinophilic asthma, eosinophilic COPD, or eosinophilic ACOS. The IL33 antagonist or combination may be used to treat or inhibit one or more of the high eosinophil subsets of eosinophilic asthma, eosinophilic COPD, or eosinophilic ACOS. The combination shows enhanced efficacy when compared to the treatment or inhibition obtained when each antibody is used alone as a monotherapy.

[0080] In some embodiments, the IL33 antagonist or a combination of an IL33 antagonist and an IL-4R antagonist is used in the manufacture of a medicament for the treatment or inhibition of any one of eosinophilic asthma, eosinophilic chronic obstructive pulmonary disease (COPD), eosinophilic asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS), hypereosinophilic eosinophilic asthma, hypereosinophilic eosinophilic COPD, hypereosinophilic eosinophilic ACOS, or nasal polyps. In a preferred embodiment, the IL33 antagonist or combination is administered to treat patients with eosinophilic asthma, eosinophilic COPD, eosinophilic ACOS, hypereosinophilic eosinophilic asthma, hypereosinophilic COPD, hypereosinophilic eosinophilic ACOS, or nasal polyps with a mutation in the intronic IL1RL1 variant rs1420101 (SEQ ID NO: 357) or a variant in linkage disequilibrium therewith, in the IL33 variant rs1342326 (SEQ ID NO: 358) or a variant in linkage disequilibrium therewith, or in the intronic IL1RL1 variant rs1420101 (SEQ ID NO: 357) or a variant in linkage disequilibrium therewith, and IL33 variant rs1342326 (SEQ ID NO: 358) or a variant in linkage disequilibrium therewith, the use of the compound in the manufacture of a medicament for such treatment or inhibition of any one of eosinophilic asthma, eosinophilic COPD, eosinophilic ACOS, hypereosinophilic eosinophilic asthma, hypereosinophilic eosinophilic COPD, hypereosinophilic eosinophilic ACOS, or nasal polyps, when the patient has one or more risk alleles associated with eosinophilic asthma, eosinophilic COPD, or eosinophilic ACOS in both IL33 variant rs1342326 (SEQ ID NO: 359) or a variant in linkage disequilibrium therewith.

[0081] According to such use, the IL33 antagonist may comprise an IL33 trap. The IL33 trap may comprise a first IL33 binding domain comprising an IL33 binding portion of IL1RL1 and a second IL33 binding domain comprising an extracellular portion of IL-1RAcP. The IL33 antagonist may instead comprise an antibody or antigen-binding fragment thereof that specifically binds to IL33. The antibody or antigen-binding fragment thereof that specifically binds to IL33 may comprise the H1, H2, and H3 domains of SEQ ID NO:274 and the L1, L2, and L3 domains of SEQ ID NO:282. The IL-4R antagonist may comprise an antibody or antigen-binding fragment thereof that specifically binds to IL-4R. The antibody or antigen-binding fragment thereof that specifically binds to IL-4R may comprise the H1, H2, and H3 domains of SEQ ID NO:337 and the L1, L2, and L3 domains of SEQ ID NO:338.

[0082] The following examples are provided to describe the present disclosure in more detail. They are intended to illustrate the present disclosure without being limiting. EXAMPLES

[0083] Example 1 Anti-IL33 antibody, anti-IL-4R antibody, and a combination of both in a model of chronic house dust mite-induced fibrosis and severe pneumonia Chronic inflammatory airway diseases are the result of recurrent episodes of airway inflammation, mainly due to repeated exposure to allergens or other pathogens.In humans, such chronic damage induces a wide range of pathologies, including lung infiltration by immune cells, cytokine production, increased mucus production and collagen deposition.The increase in inflammatory cytokines and immune cell infiltrates, accompanied by strong airway remodeling, leads to airway narrowing, hypersensitivity to inhaled triggers such as allergens or pathogens, airway obstruction and loss of lung function.

[0084] To determine the effect of anti-IL33 inhibition in a relevant in vivo model, chronic house dust mite extract (HDM)-induced fibrosis and severe lung inflammation and remodeling studies were performed in mice homozygous for expressing human IL33 instead of mouse IL33 (IL33 HumIn mice). See US Publication Nos. 2015 / 0320021 and 2015 / 0320022. Chronic HDM extract exposure induces severe lung inflammation, leading to extensive cell infiltration, cytokine expression, and remodeling. The efficacy of anti-IL33 antibodies, anti-mouse IL-4Rα antibodies, or a combination of both, was compared in this model. The anti-mouse IL-4Rα antibody used in this study is designated M1M1875N and contains the HCVR / LCVR amino acid sequence pair of SEQ ID NO: 335 / 336. The anti-IL33 antibody used in this study is designated H4H9675P and comprises the HCVR / LCVR amino acid sequence pair of SEQ ID NOs:274 / 282.

[0085] IL33 HumIn mice were intranasally administered either 50 μg of house dust mite extract (HDM, Greer, #XPB70D3A2.5) diluted in 20 μL of 1× phosphate buffered saline (PBS) or 20 μL of 1× PBS, 3 days per week for 15 weeks. A second control group of IL33 HumIn mice was administered 50 μg of HDM extract diluted in 20 μL of 1× PBS, 3 days per week for 11 weeks and disease severity was assessed at the start of antibody treatment. Four groups of HDM-challenged mice were subcutaneously injected with 25 mg / kg of either the anti-IL33 antibody H4H9675P, the anti-mouse IL-4Rα antibody M1M1875N, a combination of both antibodies, or an isotype control antibody, starting 11 weeks after HDM challenge and then twice a week (4 weeks of antibody treatment) until the end of HDM challenge. On day 108 of the study, all mice were sacrificed and their lungs were harvested. The experimental dosing and treatment protocols for the mouse groups are shown in Table 3.

[0086] [Table 3]

[0087] Lung collections for cytokine analysis. Elevated pulmonary levels of key mediators, such as the classic type 2 cytokines IL-4, IL-5, and IL-13, as well as cytokines more characteristic of type 1 immune responses such as IL-1β or TNFα, have been implicated in the development of lung disease in humans. Pulmonary levels of these proinflammatory cytokines were measured in this study.

[0088] After exsanguination, the anterior and median lobes of the right lung were removed from each mouse and placed in a tube containing a solution of tissue protein extraction reagent (1x T-PER Reagent, Pierce, #78510) supplemented with 1x Halt protease inhibitor cocktail (Thermo Scientific, #87786). All subsequent steps were performed on ice. The volume of T-PER Reagent (containing protease inhibitor cocktail) was adjusted for each sample to match a tissue to T-PER ratio of 1:7 (w / v). Lung samples were analyzed using a TissueLyser II (Qiagen Cells were mechanically disrupted using a centrifuge (#85300). The resulting lysate was centrifuged to pellet debris. The supernatant containing the soluble protein extract was transferred to a new tube and stored at 4°C until further analysis.

[0089] The total protein content in the lung protein extracts was measured using the Bradford assay. For the assay, 10 μL of diluted extract samples were plated in duplicate in a 96-well plate and mixed with 200 μL of 1× dye reagent (Biorad, #500-0006). Serial dilutions of bovine serum albumin (BSA, Sigma, #A7979) starting at 700 μg / mL in 1× T-Per reagent were used as standards to determine the protein concentration of the extracts. After 5 minutes of incubation at room temperature, the absorbance at 595 nm was measured on a Molecular Devices SPECTRAMAX® M5 plate reader. Data analysis to determine the total protein content of the lung extracts based on the BSA standard was performed using GraphPad Prism™ software.

[0090] Cytokine concentrations in lung protein extracts were measured using the Proinflammatory Panel1 (mouse) multiplex immunoassay kit (MesoScale Discovery, #K15048G-2) and custom mouse 6-plex MULTI-SPOT® immunoassay kit (MesoScale Discovery, #K152A41-4) according to the manufacturer's instructions. Briefly, 50 μL / well of calibrators and samples (diluted in Diluent41) were added to the capture antibody pre-coated plates and incubated at room temperature for 2 hours with shaking at 700 rpm. The plates were then washed three times with 1×PBS containing 0.05% (w / v) TWEEN®-20 surfactant, followed by the addition of 25 μL of detection antibody solution diluted in Diluent45. After 2 hours of incubation at room temperature with shaking, the plates were washed three times and 150 μL of 2× read buffer was added to each well. Electrochemiluminescence was read immediately on an MSD Spector instrument. Data analysis was performed using Graphpad Prism software.

[0091] The concentrations of each cytokine in total lung protein extracts from all mice in each group were normalized to the total protein content of the extracts as measured by Bradford assay and expressed as mean pg of cytokine per mg of total lung protein (pg / mg lung protein, ±SD) for each group, as shown in Table 4.

[0092] Pulmonary cytokine analysis. As shown in Table 4, the levels of cytokines and chemokines IL-4, IL-5, IL-6, IL-1β and MCP-1 released in the lungs of IL33 HumIn mice subjected to 15 weeks of HDM with or without treatment with isotype control antibody were significantly higher than in IL33 HumIn mice challenged with 1×PBS alone. Similarly, there was a trend towards increased release of cytokines IL-13 and TNFα in the lungs of IL33 HumIn mice subjected to 15 weeks of HDM. In contrast, the levels of IL-6, IL-13 and MCP-1 were significantly decreased in the lungs of IL33 HumIn mice treated with a combination of anti-IL33 and anti-mouse IL-4Rα antibodies during the last 4 weeks of chronic HDM challenge, when compared to IL33 HumIn mice administered HDM with isotype control antibody during this period. IL33 HumIn mice treated with a combination of anti-IL33 and anti-mouse IL-4Rα antibodies tended to have decreased lung levels of IL-4, IL-5, IL-1β, and TNFα during the last 4 weeks of chronic HDM challenge when compared to IL33 HumIn mice administered HDM with an isotype control antibody during this period. The effect on lung cytokines observed with the combination of anti-IL33 and anti-mouse IL-4Rα antibodies was greater than treatment with either of the individual antibodies alone.

[0093] [Table 4-1]

[0094] [Table 4-2]

[0095] Lung harvest for gene expression analysis. After exsanguination, the right lung accessory lobe was removed from each mouse, placed in a tube containing 400 μL of RNA Later (Ambion, #AM7020) and stored at -20°C until processing. Tissues were homogenized in TRIzol and chloroform was used for phase separation. The aqueous phase containing total RNA was purified using MagMAX™-96 for Microarrays Total RNA Isolation Kit (Ambion by Life Technologies, #AM1839) according to the manufacturer's specifications. Genomic DNA was removed using MagMAX™ Turbo™ DNase Buffer and TURBO DNase from the MagMAX kit listed above. mRNA (up to 2.5 μg) was reverse transcribed to cDNA using SuperScript® VILO™ Master Mix (Invitrogen by Life Technologies, #11755500). cDNA was diluted to 2ng / μL and 10ng of cDNA was incubated with TaqMan® Gene Expression Master Mix (Applied Biosystems by Life Technologies, #4369542) and relevant probes (Life Technologies, mouse B2m: Mm00437762_m1, mouse Il4: Mm00445259_m1, mouse Il5: Mm00439646_m1, mouse Il13: Mm00434204_m1, mouse Il9: Mm00434305_m1, mouse Il6: Mm00446190_m1, mouse Ccl2: Mm00441242_m1, mouse Ccl11: Mm00441242_m1, mouse Ccl2: Mm00441242_m1, mouse Ccl3: Mm00441242_m1, mouse Ccl4: Mm00441242_m1, mouse Ccl5: Mm00441242_m1, mouse Ccl6: Mm00441242_m1, mouse Ccl7: Mm00441242_m1, mouse Ccl8: Mm00441242_m1, mouse Ccl9: Mm00441242_m1, mouse Ccl10: Mm00441242_m1, mouse Ccl11: Mm00441242_m1, mouse Ccl12: Mm00441242_m1, mouse Ccl13: Mm00441242_m1, mouse Ccl14: Mm00441242_m1, mouse Ccl15: Mm00441242_m1, mouse Ccl16: Mm00441242_m1, mouse Ccl17: M The following primers were used to amplify the cDNAs: mouse Ccl24: Mm00444701_m1, mouse Tnf: Mm00443258_m1, mouse Tgfb1: Mm01178820_m1, mouse Il1rl1: Mm00516117_m1, mouse Il13ra2: Mm00515166_m1, mouse Col15a1: Mm00456584_m1, and mouse Col24a1: Mm01323744_m1) using an ABI 7900HT Sequence Detection System (Applied Biosystems).B2m was used as an internal control gene to normalize any cDNA input differences. The reference group used to normalize all samples was the average of group 1 samples ("1x PBS loading"). Expression of each gene was normalized to B2m expression within the same sample and expressed relative to its normalized expression in the reference group (mean ± SD) as shown in Table 5.

[0096] Pulmonary gene expression analysis. As shown in Table 5, the expression levels of cytokine, chemokine and collagen genes Il4, Il13, Il6, Ccl2, Tgfb1, Il13ra2 and Col24a1 in the lungs of IL33 HumIn mice subjected to 15 weeks of HDM with or without treatment with isotype control antibody were significantly increased compared to IL33 HumIn mice challenged with 1×PBS alone. Similarly, there was a trend towards increased expression of genes Il5, Il9, Ccl11, Ccl24, Tnf, Il1rl1 and Col15a1 in the lungs of IL33 HumIn mice subjected to 15 weeks of HDM.

[0097] In contrast, expression levels of Il6, Ccl2, Ccl11 and Ccl24 were significantly decreased in the lungs of IL33 HumIn mice treated with a combination of anti-IL33 and anti-mouse IL-4Rα antibodies during the last 4 weeks of chronic HDM challenge, when compared to IL33 HumIn mice administered HDM with isotype control antibody during this period. There was a trend toward decreased expression levels of Il4, Il5, Il13, Il9, Tnf, Tgfb1, Il1rl1, Il13ra2, Col15a1 and Col24a1 in mice treated with a combination of anti-IL33 and anti-mouse IL-4Rα antibodies during the last 4 weeks of chronic HDM challenge, when compared to IL33 HumIn mice administered HDM with isotype control antibody during this period. The effect on gene expression observed with the combination of anti-IL33 and anti-mouse IL-4Rα antibodies was greater than treatment with either of the individual antibodies alone.

[0098] [Table 5-1]

[0099] [Table 5-2]

[0100] [Table 5-3]

[0101] Lung harvest for pulmonary cellular infiltrate analysis. Pulmonary infiltration by immune cells is observed in many airway inflammatory diseases, including asthma and COPD. Neutrophilic pneumonia is associated with reduced lung function and severe tissue remodeling in asthmatic patients. Eosinophilic pneumonia is a hallmark of type 2 inflammation commonly seen in atopic diseases. In humans, high CD4 / CD8 ratios are observed in patients with granulomatous lung disease and other chronic inflammatory conditions. Flow cytometry was used in this study to determine the level of cellular infiltration in the lungs of HDM-exposed mice.

[0102] After exsanguination, the posterior lobe of the right lung was removed from each mouse, cut into small cubes of approximately 2-3 mm size, and then placed in a tube containing a solution of 20 μg / mL DNAse (Roche, #10104159001) and 0.7 U / mL Liberase TH (Roche, #05401151001) diluted in Hank's Balanced Salt Solution (HBSS) (Gibco, #14025), which was incubated in a 37°C water bath for 20 min and vortexed every 5 min. The reaction was stopped by adding ethylenediaminetetraacetic acid (EDTA, Gibco, #15575) to a final concentration of 10 mM. Each lung was then dissociated using a gentleMACS dissociator (Miltenyi Biotec, #130-095-937), then filtered through a 70 μm filter and centrifuged. The resulting lung pellet was resuspended in 1 mL of 1x red blood cell lysis buffer (Sigma, #R7757) to remove red blood cells. After 3 min incubation at room temperature, 3 mL of 1x DMEM was added to inactivate the red blood cell lysis buffer. The cell suspension was then centrifuged and the resulting cell pellet was resuspended in 5 mL of MACS buffer (autoMACS Running Buffer, Miltenyi Biotec, #130-091-221). The resuspended sample was filtered through a 70 μm filter and 1x10 cells were collected per well. 6Cells were seeded in 96-well V-bottom plates. Cells were then centrifuged and the pellet was washed with 1×PBS. After a second centrifugation, the cell pellet was resuspended in 100 μL of LIVE / DEAD Fixable Blue Dead Cell Stain (Life Technologies, #L23105) diluted 1:500 in 1×PBS and incubated for 20 minutes at room temperature protected from light to determine cell viability. After one wash with 1×PBS, cells were incubated for 10 minutes at 4° C. in a solution of MACS buffer containing 10 μg / mL purified rat anti-mouse CD16 / CD32Fc Block (clone: ​​2.4G2, BD Biosciences, #553142). Cells were then incubated for 30 minutes at 4° C. in the appropriate 2× antibody mix (listed in Table 6) diluted in MACS buffer protected from light. After antibody incubation, cells were washed twice with MACS buffer, resuspended in BD CytoFix (BD Biosciences, #554655), and then incubated protected from light for 15 minutes at 4° C. Cells were then washed and resuspended in MACS buffer and then transferred to BD FACS tubes (BD Biosciences, #352235) for analysis of cellular infiltrates by flow cytometry.

[0103] CD4 and CD8 T cells were analyzed using live cells with CD45 + , S.S.C. Lo , F.S.C. Lo , CD3 + , CD19 - , CD4 + , CD8 - and CD45 in live cells + , S.S.C. Lo , F.S.C. Lo , CD3 + , CD19 - , CD4 - , CD8 + Activated CD4 T cells were defined as cells that express CD45 + , S.S.C. Lo , F.S.C. Lo , CD3 + , CD19 -, CD4 + , CD8 - , and CD69 + Activated CD8 T cells were defined as cells that express CD45 + , S.S.C. Lo , F.S.C. Lo , CD3 + , CD19 - , CD4 - , CD8 + , and CD69 + Activated B cells were defined as live B cells expressing CD45 + , S.S.C. Lo , F.S.C. Lo , CD3 - , CD19 + , and CD69 + ST2+CD4+ T cells were defined as cells that express CD45 + , S.S.C. Lo , F.S.C. Lo , CD3+, CD19-, ST2+ and CD4 + Eosinophils were defined as cells that express CD45 + , GR1 - , CD11c lo , SiglecF hi Alveolar macrophages were defined as viable cells expressing CD45 + , GR1 - , CD11c Hi , SiglecF hi The activated cell data were calculated as the ratio of activated cells (CD69) in the total population (CD4). + ) (±SD). Data for ST2+CD4+ T cells were collected from T cells (viable CD45 + , S.S.C. Lo , F.S.C. Lo Data are expressed as the frequency of live cells (defined as cells that are CD4+, CD3+ and CD19-). Data for eosinophils and alveolar macrophages are expressed as the frequency of live cells. CD4 / CD8 T cell ratios are calculated as the ratio of CD4 T cell frequency to CD8 T cell frequency within the live population. All data are shown in Table 7.

[0104] [Table 6]

[0105] Lung cell infiltrate analysis. As shown in Table 7, the frequency of eosinophils, activated B cells, activated CD8 cells, ST2+Cd4+T cells and CD4 / CD8T cell ratio in the lungs of IL33 HumIn mice on HDM for 15 weeks with or without isotype control antibody treatment was significantly higher than that in IL33 HumIn mice challenged with 1×PBS alone. Similarly, the frequency of activated CD4T cells tended to increase in the lungs of IL33 HumIn mice on HDM for 15 weeks. The frequency of alveolar macrophages detected by flow cytometry tended to decrease in the lungs of IL33 HumIn mice on HDM for 15 weeks with or without isotype control antibody treatment. The frequency of alveolar macrophages was significantly increased in the lungs of IL33 HumIn mice treated with a combination of anti-IL33 and anti-mouse IL-4Rα antibodies during the last 4 weeks of chronic HDM challenge, when compared to IL33 HumIn mice administered HDM with isotype control antibody during this period. Similarly, the frequency of eosinophils, activated CD4 and CD8 T cells, activated B cells, ST2+CD4+ T cells, as well as the CD4 / CD8 T cell ratio tended to be decreased in the lungs of mice treated with a combination of anti-IL33 and anti-mouse IL-4Rα antibodies during the last 4 weeks of chronic HDM challenge, when compared to IL33 HumIn mice administered HDM with isotype control antibody during this period. The effects observed with the combination of anti-IL33 and anti-mouse IL-4Rα antibodies on the frequencies of eosinophils, alveolar macrophages, activated CD8+ T cells, ST2+ CD4+ T cells, and the CD4 / CD8 cell ratio in the lungs tend to be more effective than treatment with either of the individual antibodies alone.

[0106] [Table 7-1]

[0107] [Table 7-2]

[0108] Lung samples were taken for quantification of histopathology. The inflammatory pattern observed in this model was accompanied by widespread and severe architectural changes in HDM-exposed lungs, with evidence of increased goblet cell metaplasia, subepithelial collagen deposition, and profound lung consolidation. These pathologies are known features of human inflammatory respiratory disease that contribute to reduced lung function and airway hyperresponsiveness.

[0109] After exsanguination, the left lung was removed and placed in a plate containing 3 mL of 4% (w / v) paraformaldehyde (Boston Bioproducts, #BM-155) in 1× phosphate-buffered saline and stored at room temperature for 3 days. Lung samples were then blotted dry and transferred to tubes containing 70% ethanol for histological analysis. Samples were sent to Histoserv, Inc (Germantown, MD) for paraffin embedding, sectioning, and periodic acid-Schiff (PAS) or hematoxylin and eosin (H&E) staining.

[0110] Quantification of goblet cell metaplasia. Goblet cell metaplasia and mucus hypersecretion are hallmarks of many lung diseases, including asthma, chronic obstructive pulmonary disease, and cystic fibrosis. Excessive mucus production leads to airway obstruction and affects several important outcomes, such as human lung function, health-related quality of life, exacerbations, hospitalizations, and mortality. PAS-positive goblet cells and total epithelial cells were counted in 1-mm lengths of the main bronchi. Goblet cell metaplasia is expressed as the frequency (%, ±SD) of PAS-positive cells in 1-mm bronchial epithelium, as shown in Table 8.

[0111] Quantification of lung consolidation. Lung consolidation includes the accumulation of solid or liquid material in the alveolar space. Lung consolidation is a composite endpoint that may reflect a combination of cellular infiltrate, hyperplasia, and mucus production, used herein as a measure of gross lesions. The fraction of lung area occupied by crystal bodies was quantified on Movat pentachrome-stained paraffin-embedded lung sections using ImageJ software (NIH, Bethesda, MD). The particle analysis function was used to measure the total lung area of ​​the sections as well as the consolidation area of ​​the sections. The fraction of consolidation lung area is determined by the ratio of both measurements, as shown in Table 8.

[0112] Quantification of subepithelial fibrosis. Subepithelial fibrosis involves excess interstitial collagen deposition beneath the lung epithelium. Increased subepithelial fibrosis has been reported to be particularly associated with asthma in humans. In this model, subepithelial fibrosis was measured on Masson's Trichrome-stained paraffin-embedded lung sections using HaLo software (Indica Labs, NM). Using the layer thickness tool, the thickness of the collagen layer beneath the bronchial epithelium was recorded multiple times at approximately 30 μm intervals across one millimeter of the main bronchus. Subepithelial fibrosis is expressed as the mean thickness (μm, ±SD) of the collagen layer beneath the epithelium as shown in Table 8.

[0113] Analysis of lung histopathology. As shown in Table 9, there was a trend towards increased goblet cell metaplasia in the lungs of IL33 HumIn mice given HDM for 15 weeks with or without treatment with isotype control antibody compared to IL33 HumIn mice challenged with 1×PBS alone. Similarly, lung consolidation as well as subepithelial collagen thickness was significantly increased in IL33 HumIn mice given HDM for 15 weeks.

[0114] In contrast, IL33 HumIn mice treated with a combination of anti-IL33 and anti-mouse IL-4Rα antibodies showed a trend toward decreased goblet cell metaplasia and subepithelial collagen thickness, as well as a trend toward greater reduction in lung consolidation, during the final 4 weeks of chronic HDM challenge, when compared to IL33 HumIn mice administered HDM with an isotype control antibody during this period. The effects on goblet cell metaplasia, lung consolidation, and subepithelial collagen thickness observed with the combination of anti-IL33 and anti-mouse IL-4Rα antibodies showed a trend toward greater efficacy than treatment with either of the individual antibodies alone.

[0115] [Table 8]

[0116] Serum collection for IgE and HDM-specific IgG1 level measurement. To determine total IgE concentration in each mouse serum sample, a sandwich ELISA OPTEIA kit (BD Biosciences, #555248) was used according to the manufacturer's instructions. Serum samples were diluted and incubated with anti-IgE capture antibody coated on a 96-well plate. Total IgE was detected with a biotinylated anti-mouse IgE secondary antibody. Purified horseradish peroxidase (HRP)-labeled mouse IgE was used as a standard. HRP activity was detected using chromogen 3,3',5,5'-tetramethylbenzidine (TMB) (BD OPTEIA substrate reagent set, BD, #555214). A stop solution of 1M sulfuric acid was then added and absorbance at 450 nm was measured on a Molecular Devices SpectraMax M5 plate reader. Data analysis was performed using Prism™ software. The mean circulating IgE levels in serum for each experimental group are expressed as ng / mL (±SD), as shown in Table 9.

[0117] ELISA was used to determine HDM-specific lgG1 levels in serum samples from each mouse. HDM (Greer, #XPB70D3A2.5) coated plates were incubated with serially diluted mouse serum samples, followed by incubation with rat anti-mouse lgG1-HRP conjugated antibody (BD Biosciences, #559626). All samples were developed with TMB solution and analyzed as described above. Relative levels of circulating lgG1 in serum were expressed as titer units (titer units were calculated by multiplying the measured OD by the dilution factor required to achieve an OD450 above two times background). The average circulating HDM-specific lgG1 levels in serum for each experimental group were calculated as titer x 10 as shown in Table 9. 6 Expressed as (±SD).

[0118] Analysis of circulating levels of IgE and HDM-specific IgG1. As shown in Table 9, circulating levels of IgE were significantly increased in the serum of IL33 HumIn mice subjected to 15 weeks of HDM with or without treatment with isotype control antibody in IL33 HumIn mice challenged with 1x PBS alone. Similarly, there was a tendency for circulating levels of HDM-specific IgG1 to increase in the serum of IL33 HumIn mice subjected to 15 weeks of HDM. In contrast, there was a significant reduction in circulating levels of IgE and a tendency for circulating levels of HDM-specific IgG1 to decrease in the serum of IL33 HumIn mice treated with a combination of anti-IL33 and anti-mouse IL-4Rα antibodies during the last 4 weeks of chronic HDM challenge, when compared with IL33 HumIn mice administered HDM with isotype control antibody.

[0119] [Table 9]

[0120] The combination of H4H9675P and anti-mIL-4Rα treatment initiated in association with severe mixed inflammation improves all measured inflammatory parameters, even decreasing them to baseline levels. Furthermore, we observe additive effects on some of the most critical endpoints, including composite lung gross lesions, goblet cell metaplasia, lung cell infiltration, and cytokine levels. Thus, blocking both pathways simultaneously has the potential to affect multiple inflammatory mediators associated with severe mixed inflammation and tissue lesions, and normalize multiple parameters to baseline.

[0121] Example 2 Genetic variants in IL33 and its receptor are associated with both eosinophilic asthma and COPD In this example, we examine the relationship between previously identified asthma risk variants in IL33 and IL1RL1 with risk of asthma, COPD, and ACOS in the largest mixed collection of such cases ever collected, in which genetic data are linked to electronic health records. We examine the significance of these variants to the eosinophil subtype of asthma, COPD, and ACOS, as well as to related upper airway diseases such as nasal polyps. In addition, we evaluate the association between predicted loss-of-function variants (pLOF) in IL1RL1 and IL33 with these diseases.

[0122] Human Genetics Study Supervision. Human Genetics studies were conducted as part of the DiscovEHR study at the Regeneron Genetics Center (RGC) and Geisinger Health System (GHS).

[0123] DiscovEHR Participants and Disease Definitions. At the time of this study, the DiscovEHR study included a total of 92,323 adult individuals enrolled in the GHS MyCode® Community Health Initiative. For the study, 86,004 and 83,339 individuals of European ancestry had phenotype, as well as exome sequencing and genotype data for analysis, respectively. Participants were recruited from outpatient primary care and specialty clinics. Eosinophil counts and disease diagnosis codes (International Classification of Diseases, Ninth Revision [ICD-9]) were extracted from the EHR, covering a median of 14 years of clinical care. The median measure of EHR-recorded eosinophil count was derived from complete blood counts after removing potentially spurious values ​​that were >3 standard deviations from the within-individual median. Case status was assigned based on ICD-9 codes if at least one of the following criteria was met: (1) problem-list entry of a diagnosis code, or (2) interview diagnosis code that initiated two separate clinical interviews on separate calendar days. Individuals were assigned to one or more of three case categories (asthma, COPD and ACOS) based on ICD-9 diagnosis codes.

[0124] Control patients for all dichotomous trait analyses were defined as individuals with none of the ICD-9 diagnosis codes for asthma or COPD. Sequencing and genotyping. Sample preparation and whole-exome sequencing were performed. Briefly, exome capture was performed using either NimbleGen probes (Roche, SeqCap VCRome) or Integrated DNA Technologies probes (IDT, xGEN Exome Research panel) with additional content according to the respective manufacturer's recommended protocol. Captured DNA was PCR amplified and quantified by qRT-PCR (Kapa Biosystems). Multiplexed samples were sequenced using 75 bp paired-end sequencing on an Illumina v4 HiSeq2500 or HiSeq X sequencer to a coverage depth sufficient to provide greater than 20× haploid read depth for >85% of the targeted bases in 96% of the samples (approximately 80× average haploid read depth of the targeted bases). Raw sequence data from each Illumina HiSeq2500 run was uploaded to the DNAnexus platform for sequence read alignment and variant identification. Raw sequence data were converted from BCL files to sample-specific FASTQ files, which were aligned to human reference build GRCh38 using BWA-mem. Single nucleotide variants (SNVs) and insertion / deletion (indel) sequence variants were identified using the Genome Analysis Toolkit. Samples with a genotype rate below 10% were excluded. For final analysis, exome data were available for 59,082 and 29,504 individuals of European ancestry, respectively, captured using the VCRome xGEN probe set.

[0125] Aliquots of DNA were genotyped using the Human OmniExpress Exome Beadchip or Global Screening Array (Illumina Corp.). For final analysis, chip data were available for 56,239 and 28,500 individuals of European ancestry assayed on the Omni and GSA BeadChips, respectively.

[0126] Study design and statistical analysis. Using OMNI and GSA chip data, we evaluated two previously identified asthma risk variants (IL33 (rs1342326) and IL1RL1 (rs1420101)) for association with obstructive pulmonary disease, other airway diseases, and circulating eosinophil counts. These variants were assessed with age, age group, and age at presentation as covariates. 2 Associations with disease were tested under additive models using logistic regression in PLINK or R, including the first four principal components for , sex, smoking status, and ancestry. Associations with genotype were tested under additive genetic models using linear (PLINK, R) models that were log-transformed and controlled for the same covariates as above. All p-values ​​are consistent with the additive genetic model. Summary statistics from analyses on both platforms were combined by meta-analysis.

[0127] Under the same statistical framework, exome data were used to identify associations between pLOF variants aggregated in IL1RL1 or IL33 and obstructive pulmonary disease outcomes and eosinophil counts. For each gene, individuals were coded as 0 if they did not have any pLOF and 1 if they were heterozygous carriers of at least one pLOF; no homozygous pLOF carriers of either IL1RL1 or IL33 were observed in this study. Summary statistics from analyses on both platforms were combined by meta-analysis.

[0128] A genetic risk score reflecting the sum of risk alleles of two independent variants (IL33 (rs1342326) and IL1RL1 (rs1420101)) was also used as a predictor of obstructive pulmonary disease outcome and eosinophil count using logistic and linear regression models and the same covariates described above. Individuals with missing genotype data for one or both variants were excluded. The effect of having one, two, three, or four risk alleles was determined separately compared with individuals with no risk alleles in any variant. Trends between increasing score and increasing eosinophil count or disease risk were tested using linear regression and the Cochran-Armitage test, respectively.

[0129] All statistical analyses were performed using PLINK software (v1.90p) or R version 3.2.1. Confirmation of previously identified asthma risk variants in IL33 and IL1RL1 using DiscovEHR eosinophil counts and EHR-defined asthma. Clinical characteristics of MyCode® participants in the DiscovEHR study are described in Figure 8. Among the 86,004 patients of European ancestry who had exome sequencing in this study, 13267 (15.4%) patients were diagnosed with asthma, 9783 (11.4%) patients with COPD, and 2993 (3.4%) patients with both asthma and COPD (referred to herein as asthma-COPD overlap syndrome, or ACOS). Among the 83,339 patients of European ancestry with chip data available for this study, 12832 (15.4%) patients were diagnosed with asthma, 9536 (11.4%) patients with COPD, and 2909 (3.5%) patients with ACOS.

[0130] The first large GWAS on asthma identified an intronic IL1RL1 variant (rs1420101) associated with both asthma and circulating eosinophil counts, and a subsequent GWAS identified an upstream IL33 variant (rs1342326) associated with asthma. In this study, we assessed the association of rs1420101 (IL1RL1) and rs1342326 (IL33) with asthma (meta-allele odds ratio (OR)). allelic ) were confirmed (95% confidence interval: 1.07 (1.04-1.11), P = 8.2 × 10 -7 and Meta-OR allelic 1.09 (1.05-1.16), P = 6.0 × 10 -6 ) (Figure 3).

[0131] Furthermore, both variants were associated with median lifetime circulating eosinophil counts (n = 66,776 individuals) (meta-beta = 0.0066 (0.0054-0.0079) eos / ml, respectively, P = 2.0 × 10 -23 and meta-beta = 0.0061 (0.0045-0.0078) eos / ml, P = 2.0 × 10 -13 ).

[0132] The association of IL33 and IL1RL1 with asthma is specific for eosinophil subsets. Eosinophilic asthma is recognized as an important subset of asthma and is thought to be associated with increased asthma severity and steroid refractoriness as well as differential response to biologic therapy. To confirm the previously described association of IL33 and IL1RL1 variants with eosinophil counts assessed independently as distinct phenotypes as well as asthma, this study next assessed whether these risks were associated by specific associations with asthmatic eosinophil subsets and therefore in subgroups of asthmatic patients stratified by high (>200eos / μL) and low (≦200eos / μL) lifetime median eosinophil counts (Figure 3). Both IL33 (rs1342326) and IL1RL1 (rs1420101) variants were significantly associated only with the eosinophilic asthma subset (for IL33, the allelic meta-odds ratio was 1.12 (1.06-1.18) in the high eosinophil group vs. 1.04 (0.98-1.09) in the low eosinophil group; for IL1RL1, the allelic odds ratio was 1.07 (1.04-1.1) in the high eosinophil group vs. 1.02 (0.98-1.06) in the low eosinophil group) (Figure 3).

[0133] Novel associations between asthma risk variants in IL33 and IL1RL1 and increased risk for COPD and ACOS, especially in eosinophil subsets. In addition to the above associations with eosinophilic asthma, IL33 (rs1342326) and IL1RL1 (rs1420101) variants were associated with increased risk of COPD (Figure 4; for IL33, meta-OR allelic = 1.04 (0.99-1.09), P = 8.9 × 10 -2 , and meta-OR for IL1RL1 allelic = 1.04 (1-1.07), P = 3.9 x 10 -2 ) and ACOS (Meta OR for IL33 in Figure 5 allelic 1.08 (1.0-1.16), P = 3.8 × 10 -2 , and for IL1RL1, 1.06 (1.0-1.12), P = 4.8 × 10 -2 ) was further found to be suggestively or marginally significantly associated with

[0134] Similar to asthma, eosinophil subsets in COPD and ACOS are associated with more severe disease. To determine whether the association of IL33 and IL1RL1 with COPD and ACOS is also specific to eosinophil subtypes, as we have confirmed in asthma, we evaluated the association between IL33 (rs1342326) and IL1RL1 (rs1420101) in COPD and ACOS subgroups stratified by high (>200eos / μL) and low (≦200eos / μL) lifetime median eosinophil counts (Figures 4 and 5). Both variants were suggestively associated with COPD and ACOS only in disease subgroups characterized by high circulating eosinophils.

[0135] A high abundance of risk-increasing alleles in the IL33 signaling pathway leads to a substantially increased risk of asthma, COPD, and ACOS. Because IL33 and IL1RL1 are part of the same signaling complex, and because these variants show a notable allele dosage dependence in their risk associations when analyzed individually, a two-variant genetic risk score was constructed by summing the number of risk alleles in IL33 (rs1342326) and IL1RL1 (rs1420101) (each individual had a score ranging from 0 to 4) and tested for associations between the score and eosinophil count and risk of asthma, COPD, and ACOS. Individuals with each genetic risk score were compared to those without the risk allele. Trend tests showed that increasing genetic risk scores were associated with increased eosinophil counts (Figure 2, P = 1 × 10 -39 ) and asthma (Fig. 6, P = 3.27 × 10 -12 ), COPD (Fig. 6, P = 6.65 × 10 -3 ), and ACOS (P = 4.3 × 10 -3 ) was significantly associated with an increased risk of eosinophil count (Figure 2). The largest effect (above nominal significance) was observed in patients with three risk alleles (metabeta = 0.0071 (0.0057-0.0085) eos / ml, P = 8.8 × 10 -24 , for asthma (Figure 6), meta-OR = 1.28 (1.17-1.41), P = 6.99 × 10 -8, for COPD (Fig. 6), OR = 1.17 (1.04-1.31), P = 9.35 × 10 -3 , and for ACOS ( Fig. 6 ), OR = 1.23 (1.03-1.48), P = 2.49 × 10 -2 ) (Figure 2). A small number of individuals carried four risk alleles, and as a result, effect size estimates had wide confidence intervals.

[0136] We also evaluated the association of the two variant scores with high and low eosinophil patient subgroups (Figure 7). Tests for trend showed that the scores were significantly associated with asthma (P = 1.37 × 10 -15 ), COPD (P = 3.9 × 10 -8 ), and ACOS (P = 1.8 × 10 -5 eosinophil subsets in asthma, COPD, or ACOS were significantly associated with high eosinophil subsets in asthma, COPD, or ACOS (P>0.05 for each disease). The greatest score-specific effect was observed in patients with three risk alleles (for high eosinophil asthma, meta-OR=1.61 (1.42-1.84), P=6.33×10 -13 , for high eosinophil COPD, meta-OR = 1.53 (1.31-1.79), P = 4.76 × 10 -8 , and for high eosinophilic ACOS, OR = 1.7 (1.34-2.14), P = 1 × 10 -5 ). As noted above, there were relatively few individuals with four risk alleles, and each effect size estimate had a wide confidence interval.

[0137] Predicted loss-of-function (pLOF) variants in IL33 are associated with reduced circulating eosinophil counts and risk of obstructive pulmonary disease. Analysis of the IL33 pLOF variant rs146597587 showed that IL33 inactivation was associated with reduced eosinophil counts (meta-beta = -0.02 (-0.03-0.0092), P = 7.3 × 10 -5), but was not significantly associated with a reduced risk of eosinophilic asthma, COPD, and ACOS (OR=0.82 (0.63-1.07), P=0.15, OR=0.99 (0.74-1.33), P=0.94, and OR=0.93 (0.56-1.53), P=0.76, respectively) (Figure 7). IL1RL1 pLOF mutations were not associated with risk of obstructive pulmonary disease.

[0138] Analysis of IL1RL1 variant rs1420101 and IL33 variant rs1342326 with other airway diseases. The unified airway theory posits that asthma may co-occur with other airway diseases due to common mechanisms. Therefore, other EHR-recorded diseases related to the airway were tested for association with rs1420101 and rs1342326 (Figure 9). IL33 variant rs1342326 and IL1RL1 variant rs1420101 were associated with increased risk of allergic rhinitis (meta-OR 1.04 (1.01-1.08), P=0.02; meta-OR 1.04 (1.01-1.06), P=2.4×10 -3 ) and increased risk of nasal polyps (meta-OR 1.48 (1.28-1.72), P = 1.2 × 10 -7 , meta-OR 1.17 (1.04-1.33), P = 1.2 × 10 -2 ). Furthermore, the dose of these common risk variants also significantly increased the risk of allergic rhinitis and nasal polyps (P = 1.45 × 10 -4 , P = 2.48 × 10 -7 These results are consistent with previous reports implicating common genetic variants in IL33 in nasal polyps risk.

[0139] SUMMARY: IL33 is thought to be involved in the barrier defense of epithelial tissues, including the lung epithelium, and is involved in the pathogenesis of asthma. Two variants described in this example, IL33 (rs1342326) and IL1RL1 (rs1420101), have previously been associated with asthma in several studies. These reproducible and independent associations with both the ligand (IL33) and its specific receptor (IL1R1), (IL33 located on chromosome 9 and IL1RL1 located on chromosome 2), suggest a role for IL33 signaling in asthma risk.

[0140] This study significantly expands on these previous findings. By performing whole-exome sequencing and genotyping in over 83,000 adult participants associated with the DiscovEHR Study, we confirmed the association between IL33 and IL1RL1 and asthma, as well as eosinophil counts assessed independently as distinct phenotypes. Furthermore, we demonstrated suggestive associations of IL33 and IL1RL1 variants with increased risk of COPD and ACOS, thus providing genetic links supporting a possible shared mechanistic etiology for all three of these highly prevalent lung diseases. We also demonstrated associations of these variants with nasal polyposis and allergic rhinitis. In addition, we found that we observed a greater effect on disease risk in individuals with a higher dose of these risk alleles across both loci. Furthermore, heterozygous carriers of rare pLOF variants in IL33 had a trend toward lower lifetime median eosinophil counts, reflecting a risk reduction of approximately 20% for asthma. We believe that these data provide genetic evidence linking the IL33 pathway to asthma, and possibly COPD, through a range of alleles that include both risk-increasing common alleles and risk-reducing rare pLOF alleles.

[0141] We believe that prior to this study, genetic variants in the IL33 pathway have not previously been associated with COPD. Similarly, we believe that there has been no prior genetic data linking either pathway with eosinophil subset risk in asthma, COPD, and ACOS. Our results suggest an association of enhanced IL33 signaling with increased risk of eosinophil subtypes in asthma and COPD, and the numerically higher risk association seen in ACOS patients suggests that this entity at the intersection of these conditions may in fact have unique characteristics. In addition to providing a unifying genetic and mechanistic association between previously clearly classified eosinophil subsets of obstructive pulmonary diseases, the data also support the principle of the "unified airway theory," which hypothesizes that eosinophilic lung diseases may represent a continuum that includes associated upper airway diseases. In this regard, we observed a significant increased risk of IL33 variants in allergic rhinitis and nasal polyps.

[0142] Although not statistically significant, the protective association with IL33 pLOF variants described here is consistent with recent studies demonstrating that rare loss-of-function variants of IL33 were protective in asthma and supports the possibility that inhibition of IL33 signaling may be an important therapeutic strategy for obstructive pulmonary diseases. The data suggest a role for blocking interleukin-33, particularly in the eosinophilic forms of obstructive pulmonary diseases such as asthma and COPD, as well as for eosinophilic upper airway diseases such as allergic rhinitis and nasal polyps.

[0143] Relatedly, recent advances in the use of biologics to treat severe and steroid-resistant asthma are believed to differentiate eosinophilic diseases. Many therapies targeting interleukin-5 and interleukin-13 are believed to benefit only the eosinophil subset of asthma patients, while an antibody that blocks both the interleukin-4 and interleukin-13 pathways (dupilumab) is believed to have a numerically greater benefit in eosinophilic patients, but also very high activity in the low eosinophil subset. These therapies are also believed to benefit nasal polyps and allergic rhinitis. Consistent with these aforementioned differences in the response of eosinophilic asthma patients to biologic therapy, the data from this example suggests that interleukin-33 blockade may be optimal for targeting the eosinophil subsets of asthma, ACOS, and COPD.

[0144] Although the study has certain limitations, it nevertheless represents a real-world clinical care situation, and IL33 and IL1RL1 genetic variants in this population are associated with an increased risk of both asthma and COPD diagnoses. For the purposes of individualizing patient treatment, whether one reaches a diagnostic label of asthma, COPD, or ACOS is likely less important than identifying the mechanistic pathology occurring in a particular patient or group of patients, and these data suggest that subsets of asthma, COPD, and ACOS patients may be driven, in part, by excessive IL33 activity. Mitigating various limitations of these data is the remarkable consistency of findings using genetic variants of two different genes within the same pathway, with similar results seen for variants in the genes for IL33 as well as its receptor. For variants in both genes, consistent risk associations were seen across multiple relevant EHR-defined disease contexts, and within these disease contexts, consistent results were also repeatedly shown to be specific to the eosinophil subsets of these diseases. Other compelling aspects of the data include the concordance and notable allele dependence of many of the risk associations, as well as the added power gained from the two variant risk score analysis. Finally, the reciprocal findings of the IL33 pLOF variants are also supportive.

[0145] These data suggest that genetic variants enhancing IL33 signaling contribute to increased risk of asthma, COPD and eosinophilic forms of ACOS, and that pLOF genetic variants in IL33 may contribute to reduced risk of these diseases, and risk of upper airway diseases such as nasal polyps also appears to be associated with IL33 signaling. Individuals with genetic variants enhancing IL33 signaling may represent an opportunity for precision medicine, as those particular asthma and COPD patients may benefit greatly from therapeutic blockade of IL33. The data also raise the possibility that patients suffering from eosinophilic airway diseases, regardless of subtype and variant status, may benefit from inhibition of IL33.

[0146] The present disclosure is not limited to the embodiments described and exemplified above, but can be varied and modified within the scope of the appended claims. U.S. Patent Application No. 15 / 827,357, filed November 30, 2017, is hereby incorporated by reference in its entirety for all purposes. (Additional Note) The technical ideas that can be understood from the above-described embodiment and modified examples will be described. [Item 1] A method for assessing a risk of developing eosinophilic asthma, allergic rhinitis, or eosinophilic asthma-COPD overlap syndrome (ACOS), comprising: (A) detecting one or more risk alleles associated with eosinophilic asthma, allergic rhinitis, or eosinophilic ACOS in an intronic IL1RL1 variant rs1420101 (SEQ ID NO: 357) or a variant in linkage disequilibrium therewith, in an IL33 variant rs1342326 (SEQ ID NO: 358) or a variant in linkage disequilibrium therewith, or in both the intronic IL1RL1 variant rs1420101 (SEQ ID NO: 357) or a variant in linkage disequilibrium therewith and the IL33 variant rs1342326 (SEQ ID NO: 358) or a variant in linkage disequilibrium therewith in a sample obtained from the subject; (B)(i) if the subject has a risk allele in the intronic IL1RL1 variant rs1420101 (SEQ ID NO: 357) in one of the chromosome 2 homologs or a variant in linkage disequilibrium therewith, or a risk allele in the IL33 variant rs1342326 (SEQ ID NO: 358) in one of the chromosome 9 homologs or a variant in linkage disequilibrium therewith, assigning the subject a risk score of 1; (B)(ii) assigning a risk score of 2 to the subject if the subject has a risk allele in the intronic IL1RL1 variant rs1420101 (SEQ ID NO: 357) or a variant in linkage disequilibrium therewith in both of the chromosome 2 homologs, if the subject has a risk allele in the IL33 variant rs1342326 (SEQ ID NO: 358) or a variant in linkage disequilibrium therewith in both of the chromosome 9 homologs, or if the subject has a risk allele in the intronic IL1RL1 variant rs1420101 (SEQ ID NO: 357) or a variant in linkage disequilibrium therewith in one of the chromosome 2 homologs and a risk allele in the IL33 variant rs1342326 (SEQ ID NO: 358) or a variant in linkage disequilibrium therewith in one of the chromosome 9 homologs; (B)(iii) assigning a risk score of 3 to the subject if the subject has a risk allele in the intronic IL1RL1 variant rs1420101 (SEQ ID NO: 357) or a variant in linkage disequilibrium therewith in both of the chromosome 2 homologs and a risk allele in the IL33 variant rs1342326 (SEQ ID NO: 358) or a variant in linkage disequilibrium therewith in one of the chromosome 9 homologs, or if the subject has a risk allele in the intronic IL1RL1 variant rs1420101 (SEQ ID NO: 357) or a variant in linkage disequilibrium therewith in one of the chromosome 2 homologs and a risk allele in the IL33 variant rs1342326 (SEQ ID NO: 358) or a variant in linkage disequilibrium therewith in both of the chromosome 9 homologs; or (B)(iv) if the subject has a risk allele in the intronic IL1RL1 variant rs1420101 (SEQ ID NO: 357) or a variant in linkage disequilibrium therewith in both of the chromosome 2 homologs and a risk allele in the IL33 variant rs1342326 (SEQ ID NO: 358) or a variant in linkage disequilibrium therewith in both of the chromosome 9 homologs, assigning the subject a risk score of 4; (C) classifying the subject's risk of developing eosinophilic asthma, allergic rhinitis, or eosinophilic ACOS, where a risk score of 1 indicates that the subject is at risk of developing the high eosinophil subset of eosinophilic asthma, the high eosinophil subset of allergic rhinitis, or the high eosinophil subset of eosinophilic ACOS, and a risk score of 2 indicates that the subject is at risk of developing the high eosinophil subset of eosinophilic asthma, the high eosinophil subset of allergic rhinitis, or the high eosinophil subset of eosinophilic ACOS. a risk score of 3 indicates that the subject is at high risk for developing the high eosinophil subset of eosinophilic asthma, the high eosinophil subset of allergic rhinitis, or the high eosinophil subset of eosinophilic ACOS; and a risk score of 4 indicates that the subject is at very high risk for developing the high eosinophil subset of eosinophilic asthma, the high eosinophil subset of allergic rhinitis, or the high eosinophil subset of eosinophilic ACOS. The method comprising: [Item 2] The method of claim 1, further comprising identifying the subject as a candidate for treatment with an IL33 antagonist or a combination of an IL33 antagonist and an IL-4R antagonist administered in an amount effective to treat or inhibit the eosinophil high subset of eosinophilic asthma, the eosinophil high subset of allergic rhinitis, or the eosinophil high subset of eosinophilic ACOS. [Item 3] The method of item 1 or item 2, further comprising administering to the subject an IL33 antagonist, or an IL33 antagonist and an IL-4R antagonist. [Item 4] The method of item 3, wherein the method comprises administering to the subject an IL33 antagonist. [Item 5] 4. The method of claim 3, wherein the method comprises administering to the subject an IL33 antagonist and an IL-4R antagonist. [Item 6] 6. The method of any one of items 2 to 5, wherein the IL33 antagonist comprises an IL33 trap. [Item 7] 7. The method of claim 6, wherein the IL33 trap comprises a first IL33 binding domain comprising the IL33 binding portion of IL1RL1 and a second IL33 binding domain comprising the extracellular portion of IL-1RAcP. [Item 8] The method according to any one of items 2 to 5, wherein the IL33 antagonist comprises an antibody or an antigen-binding fragment thereof that specifically binds to IL33. [Item 9] 9. The method of claim 8, wherein the antibody or antigen-binding fragment thereof that specifically binds to IL33 comprises the H1, H2, and H3 domains of SEQ ID NO: 274 and the L1, L2, and L3 domains of SEQ ID NO: 282. [Item 10] 10. The method of any one of items 2, 3, or 5 to 9, wherein the IL-4R antagonist comprises an antibody or an antigen-binding fragment thereof that specifically binds to IL-4R. [Item 11] 11. The method of claim 10, wherein the antibody or antigen-binding fragment thereof that specifically binds to IL-4R comprises the H1, H2, and H3 domains of SEQ ID NO: 337 and the L1, L2, and L3 domains of SEQ ID NO: 338. [Item 12] 12. The method of any one of items 1 to 11, further comprising detecting an increased level of eosinophil count from blood or sputum isolated from the subject. [Item 13] 1. A method of treating or inhibiting eosinophilic asthma, comprising administering an IL33 antagonist to a subject having one or more risk alleles associated with eosinophilic asthma in intronic IL1RL1 variant rs1420101 (SEQ ID NO: 357) or a variant in linkage disequilibrium therewith, in IL33 variant rs1342326 (SEQ ID NO: 358) or a variant in linkage disequilibrium therewith, or in both the intronic IL1RL1 variant rs1420101 (SEQ ID NO: 357) or a variant in linkage disequilibrium therewith and the IL33 variant rs1342326 (SEQ ID NO: 358) or a variant in linkage disequilibrium therewith, wherein eosinophilic asthma is treated or inhibited in the subject. [Item 14] The method of claim 13, wherein the subject has at least one risk allele associated with eosinophilic asthma in the IL1RL1 variant rs1420101 (SEQ ID NO: 357) or a variant in linkage disequilibrium therewith. [Item 15] The method of claim 13 or 14, wherein the subject has two risk alleles associated with eosinophilic asthma in the IL1RL1 variant rs1420101 (SEQ ID NO: 357) or a variant in linkage disequilibrium therewith. [Item 16] The method of claim 13, wherein the subject has at least one risk allele associated with eosinophilic asthma in the IL33 variant rs1342326 (SEQ ID NO: 358) or a variant in linkage disequilibrium therewith. [Item 17] The method of claim 13 or 16, wherein the subject has two risk alleles associated with eosinophilic asthma in the IL33 variant rs1342326 (SEQ ID NO: 358) or a variant in linkage disequilibrium therewith. [Item 18] The method of claim 14 or 15, wherein the subject further has at least one risk allele associated with eosinophilic asthma in the IL33 variant rs1342326 (SEQ ID NO: 358) or a variant in linkage disequilibrium therewith. [Item 19] 19. The method of any one of items 14, 15, or 18, wherein the subject further has two risk alleles associated with eosinophilic asthma in the IL33 variant rs1342326 (SEQ ID NO: 358) or a variant in linkage disequilibrium therewith. [Item 20] 20. The method according to any one of items 13 to 19, wherein the method comprises administering to the subject an IL33 antagonist. [Item 21] 20. The method according to any one of items 13 to 19, wherein the method comprises administering to the subject an IL33 antagonist and an IL-4R antagonist. [Item 22] 22. The method of any one of items 13 to 21, wherein the IL33 antagonist comprises an IL33 trap. [Item 23] 23. The method of claim 22, wherein the IL33 trap comprises a first IL33 binding domain comprising the IL33 binding portion of IL1RL1 and a second IL33 binding domain comprising the extracellular portion of IL-1RAcP. [Item 24] 22. The method of any one of items 13 to 21, wherein the IL33 antagonist comprises an antibody or an antigen-binding fragment thereof that specifically binds to IL33. [Item 25] 25. The method of claim 24, wherein the antibody or antigen-binding fragment thereof that specifically binds to IL33 comprises the H1, H2, and H3 domains of SEQ ID NO: 274 and the L1, L2, and L3 domains of SEQ ID NO: 282. [Item 26] The method of any one of items 13 to 19 or 21 to 25, wherein the IL-4R antagonist comprises an antibody or an antigen-binding fragment thereof that specifically binds to IL-4R. [Item 27] 27. The method of claim 26, wherein the antibody or antigen-binding fragment thereof that specifically binds to IL-4R comprises the H1, H2, and H3 domains of SEQ ID NO: 337 and the L1, L2, and L3 domains of SEQ ID NO: 338. [Item 28] 1. A method for treating or inhibiting allergic rhinitis, comprising administering an IL33 antagonist to a subject having one or more risk alleles associated with allergic rhinitis in intronic IL1RL1 variant rs1420101 (SEQ ID NO: 357) or a variant in linkage disequilibrium therewith, in IL33 variant rs1342326 (SEQ ID NO: 358) or a variant in linkage disequilibrium therewith, or in both the intronic IL1RL1 variant rs1420101 (SEQ ID NO: 357) or a variant in linkage disequilibrium therewith and the IL33 variant rs1342326 (SEQ ID NO: 358) or a variant in linkage disequilibrium therewith, or administering an IL33 antagonist and an IL-4R antagonist, wherein allergic rhinitis is treated or inhibited in the subject. [Item 29] 29. The method of claim 28, wherein the subject has at least one risk allele associated with allergic rhinitis in the IL1RL1 variant rs1420101 (SEQ ID NO: 357) or a variant in linkage disequilibrium therewith. [Item 30] 30. The method of claim 28 or 29, wherein the subject has two risk alleles associated with allergic rhinitis in the IL1RL1 variant rs1420101 (SEQ ID NO: 357) or a variant in linkage disequilibrium therewith. [Item 31] 29. The method of claim 28, wherein the subject has at least one risk allele associated with allergic rhinitis in the IL33 variant rs1342326 (SEQ ID NO: 358) or a variant in linkage disequilibrium therewith. [Item 32] 32. The method of claim 28 or 31, wherein the subject has two risk alleles associated with allergic rhinitis in the IL33 variant rs1342326 (SEQ ID NO: 358) or a variant in linkage disequilibrium therewith. [Item 33] 32. The method of claim 29 or 31, wherein the subject further has at least one risk allele associated with allergic rhinitis in the IL33 variant rs1342326 (SEQ ID NO: 358) or a variant in linkage disequilibrium therewith. [Item 34] 34. The method of any one of items 29, 30, or 33, wherein the subject further has two risk alleles associated with allergic rhinitis in the IL33 variant rs1342326 (SEQ ID NO: 358) or a variant in linkage disequilibrium therewith. [Item 35] 35. The method of any one of items 28 to 34, wherein the method comprises administering to the subject an IL33 antagonist. [Item 36] 35. The method according to any one of items 28 to 34, wherein the method comprises administering to the subject an IL33 antagonist and an IL-4R antagonist. [Item 37] 37. The method of any one of items 28 to 36, wherein the IL33 antagonist comprises an IL33 trap. [Item 38] 38. The method of claim 37, wherein the IL33 trap comprises a first IL33 binding domain comprising the IL33 binding portion of IL1RL1 and a second IL33 binding domain comprising the extracellular portion of IL-1RAcP. [Item 39] 37. The method of any one of items 28 to 36, wherein the IL33 antagonist comprises an antibody or an antigen-binding fragment thereof that specifically binds to IL33. [Item 40] 40. The method of claim 39, wherein the antibody or antigen-binding fragment thereof that specifically binds to IL33 comprises the H1, H2, and H3 domains of SEQ ID NO: 274 and the L1, L2, and L3 domains of SEQ ID NO: 282. [Item 41] The method of any one of items 28 to 34 or 36 to 40, wherein the IL-4R antagonist comprises an antibody or an antigen-binding fragment thereof that specifically binds to IL-4R. [Item 42] 42. The method of claim 41, wherein the antibody or antigen-binding fragment thereof that specifically binds to IL-4R comprises the H1, H2, and H3 domains of SEQ ID NO: 337 and the L1, L2, and L3 domains of SEQ ID NO: 338. [Item 43] 1. A method of treating or inhibiting eosinophilic asthma-chronic obstructive pulmonary disease (COPD) overlap syndrome (ACOS), comprising administering an IL33 antagonist to a subject having one or more risk alleles associated with eosinophilic asthma in intronic IL1RL1 variant rs1420101 (SEQ ID NO: 357) or a variant in linkage disequilibrium therewith, in IL33 variant rs1342326 (SEQ ID NO: 358) or a variant in linkage disequilibrium therewith, or in both the intronic IL1RL1 variant rs1420101 (SEQ ID NO: 357) or a variant in linkage disequilibrium therewith and the IL33 variant rs1342326 (SEQ ID NO: 358) or a variant in linkage disequilibrium therewith, wherein eosinophilic COPD is treated or inhibited in the subject. [Item 44] The method of claim 43, wherein the subject has at least one risk allele associated with eosinophilic ACOS in the IL1RL1 variant rs1420101 (SEQ ID NO: 357) or a variant in linkage disequilibrium therewith. [Item 45] The method of claim 43 or 44, wherein the subject has two risk alleles associated with eosinophilic ACOS in the IL1RL1 variant rs1420101 (SEQ ID NO: 357) or a variant in linkage disequilibrium therewith. [Item 46] The method of claim 43, wherein the subject has at least one risk allele associated with eosinophilic ACOS in the IL33 variant rs1342326 (SEQ ID NO: 358) or a variant in linkage disequilibrium therewith. [Item 47] The method of claim 43 or 46, wherein the subject has two risk alleles associated with eosinophilic ACOS in the IL33 variant rs1342326 (SEQ ID NO: 358) or a variant in linkage disequilibrium therewith. [Item 48] The method of claim 44 or 45, wherein the subject further has at least one risk allele associated with eosinophilic ACOS in the IL33 variant rs1342326 (SEQ ID NO: 358) or a variant in linkage disequilibrium therewith. [Item 49] The method of any one of items 44, 45, or 48, wherein the subject further has two risk alleles associated with eosinophilic ACOS in the IL33 variant rs1342326 (SEQ ID NO: 358) or a variant in linkage disequilibrium therewith. [Item 50] 50. The method according to any one of items 43 to 49, wherein the method comprises administering to the subject an IL33 antagonist. [Item 51] 50. The method according to any one of items 43 to 49, wherein the method comprises administering to the subject an IL33 antagonist and an IL-4R antagonist. [Item 52] 52. The method of any one of items 43 to 51, wherein the IL33 antagonist comprises an IL33 trap. [Item 53] 53. The method of claim 52, wherein the IL33 trap comprises a first IL33 binding domain comprising the IL33 binding portion of IL1RL1 and a second IL33 binding domain comprising the extracellular portion of IL-1RAcP. [Item 54] 52. The method of any one of items 43 to 51, wherein the IL33 antagonist comprises an antibody or an antigen-binding fragment thereof that specifically binds to IL33. [Item 55] 55. The method of claim 54, wherein the antibody or antigen-binding fragment thereof that specifically binds to IL33 comprises the H1, H2, and H3 domains of SEQ ID NO: 274 and the L1, L2, and L3 domains of SEQ ID NO: 282. [Item 56] 56. The method of any one of items 43 to 49 or 51 to 55, wherein the IL-4R antagonist comprises an antibody or an antigen-binding fragment thereof that specifically binds to IL-4R. [Item 57] 57. The method of claim 56, wherein the antibody or antigen-binding fragment thereof that specifically binds to IL-4R comprises the H1, H2, and H3 domains of SEQ ID NO: 337 and the L1, L2, and L3 domains of SEQ ID NO: 338. [Item 58] A patient with eosinophilic asthma, allergic rhinitis, eosinophilic asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS), hypereosinophilic eosinophilic asthma, hypereosinophilic allergic rhinitis, hypereosinophilic eosinophilic ACOS, or nasal polyps is diagnosed with a IL33 variant rs1342326 (SEQ ID NO: 358) or a variant in linkage disequilibrium therewith, or a IL33 variant rs1342326 (SEQ ID NO: 359) or a variant in linkage disequilibrium therewith and a variant in intronic IL1RL1 variant rs1420101 (SEQ ID NO: 357) or a variant in linkage disequilibrium therewith and a variant in intronic IL1RL1 variant rs1420101 (SEQ ID NO: 357) or a variant in linkage disequilibrium therewith and a variant in intronic IL1RL1 variant rs1420101 (SEQ ID NO: 358 ... An IL33 antagonist or a combination of an IL33 antagonist and an IL-4R antagonist for use in treating or inhibiting any one of eosinophilic asthma, allergic rhinitis, eosinophilic asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS), hypereosinophilic eosinophilic asthma, hypereosinophilic allergic rhinitis, hypereosinophilic eosinophilic ACOS, or nasal polyps, in a patient having one or more risk alleles associated with eosinophilic asthma, allergic rhinitis, or eosinophilic ACOS in both the IL33 variant rs1342326 (SEQ ID NO: 358) or a variant in linkage disequilibrium therewith. [Item 59] 59. An IL33 antagonist or a combination of an IL33 antagonist and an IL-4R antagonist according to item 58 for use in the treatment or inhibition of eosinophilic asthma. [Item 60] 59. An IL33 antagonist or a combination of an IL33 antagonist and an IL-4R antagonist according to item 58 for use in the treatment or inhibition of allergic rhinitis. [Item 61] 59. An IL33 antagonist or a combination of an IL33 antagonist and an IL-4R antagonist according to item 58 for use in the treatment or inhibition of eosinophilic ACOS. [Item 62] 59. An IL33 antagonist or a combination of an IL33 antagonist and an IL-4R antagonist according to item 58 for use in the treatment or inhibition of hypereosinophilic eosinophilic asthma. [Item 63] 59. An IL33 antagonist or a combination of an IL33 antagonist and an IL-4R antagonist according to item 58 for use in the treatment or inhibition of hypereosinophilic allergic rhinitis. [Item 64] 59. The IL33 antagonist or the combination of an IL33 antagonist and an IL-4R antagonist according to item 58 for use in the treatment or inhibition of hypereosinophilic eosinophilic ACOS. [Item 65] 59. An IL33 antagonist or a combination of an IL33 antagonist and an IL-4R antagonist according to item 58 for use in the treatment or inhibition of nasal polyps. [Item 66] 66. The IL33 antagonist or a combination of an IL33 antagonist and an IL-4R antagonist according to any one of items 58 to 65, wherein said IL33 antagonist comprises an IL33 trap. [Item 67] 67. The IL33 antagonist or the combination of an IL33 antagonist and an IL-4R antagonist according to item 66, wherein the IL33 trap comprises a first IL33 binding domain comprising the IL33 binding portion of IL1RL1 and a second IL33 binding domain comprising the extracellular portion of IL-1RAcP. [Item 68] 66. The IL33 antagonist or a combination of an IL33 antagonist and an IL-4R antagonist according to any one of items 58 to 65, wherein the IL33 antagonist comprises an antibody or an antigen-binding fragment thereof that specifically binds to IL33. [Item 69] 69. The IL33 antagonist or the combination of an IL33 antagonist and an IL-4R antagonist according to item 68, wherein the antibody or antigen-binding fragment thereof comprises the H1, H2, and H3 domains of SEQ ID NO: 274 and the L1, L2, and L3 domains of SEQ ID NO: 282. [Item 70] 70. The IL33 antagonist or a combination of an IL33 antagonist and an IL-4R antagonist according to any one of items 58 to 69, wherein the IL-4R antagonist comprises an antibody or an antigen-binding fragment thereof that specifically binds to IL-4R. [Item 71] 71. The IL33 antagonist or the combination of an IL33 antagonist and an IL-4R antagonist according to item 70, wherein the antibody or antigen-binding fragment thereof that specifically binds to IL-4R comprises the H1, H2, and H3 domains of SEQ ID NO: 337 and the L1, L2, and L3 domains of SEQ ID NO: 338.

Claims

1. 1. A medicament for use in treating or inhibiting nasal polyps in a subject, comprising a combination of an IL33 antagonist and an IL-4R antagonist; the subject has i) intronic IL1RL1 variant rs1420101 or a variant in linkage disequilibrium therewith, and ii) IL33 variant rs1342326 or a variant in linkage disequilibrium therewith; the IL33 antagonist comprises an IL33 trap comprising a first IL33 binding domain comprising an IL33 binding portion of IL1RL1 and a second IL33 binding domain comprising an extracellular portion of IL-1RAcP, or the IL33 antagonist comprises an antibody or antigen-binding fragment thereof that specifically binds to IL33, and The IL-4R antagonist comprises an antibody or an antigen-binding fragment thereof that specifically binds to IL-4R.

2. The pharmaceutical according to claim 1, wherein the antibody or antigen-binding fragment thereof that specifically binds to IL33 comprises a heavy chain complementarity determining region comprising the amino acid sequence of SEQ ID NO:274 and a light chain complementarity determining region comprising the amino acid sequence of SEQ ID NO:

282.

3. The pharmaceutical according to claim 1 or 2, wherein the antibody or antigen-binding fragment thereof that specifically binds to IL-4R comprises a heavy chain complementarity determining region comprising the amino acid sequence of SEQ ID NO: 337 and a light chain complementarity determining region comprising the amino acid sequence of SEQ ID NO:

338.

4. The pharmaceutical agent according to any one of claims 1 to 3, wherein the anti-IL-4R antibody comprises dupilumab.

5. 1. A medicament for use in treating or inhibiting allergic rhinitis in a subject, comprising a combination of an IL33 antagonist and an IL-4R antagonist, the subject has i) intronic IL1RL1 variant rs1420101 or a variant in linkage disequilibrium therewith, and ii) IL33 variant rs1342326 or a variant in linkage disequilibrium therewith; the IL33 antagonist comprises an IL33 trap comprising a first IL33 binding domain comprising an IL33 binding portion of IL1RL1 and a second IL33 binding domain comprising an extracellular portion of IL-1RAcP, or the IL33 antagonist comprises an antibody or antigen-binding fragment thereof that specifically binds to IL33, and The IL-4R antagonist comprises an antibody or an antigen-binding fragment thereof that specifically binds to IL-4R.

6. The pharmaceutical according to claim 5, wherein the antibody or antigen-binding fragment thereof that specifically binds to IL33 comprises a heavy chain complementarity determining region comprising the amino acid sequence of SEQ ID NO: 274 and a light chain complementarity determining region comprising the amino acid sequence of SEQ ID NO:

282.

7. The pharmaceutical according to claim 5 or 6, wherein the antibody or antigen-binding fragment thereof that specifically binds to IL-4R comprises a heavy chain complementarity determining region comprising the amino acid sequence of SEQ ID NO: 337 and a light chain complementarity determining region comprising the amino acid sequence of SEQ ID NO:

338.

8. The pharmaceutical agent according to any one of claims 5 to 7, wherein the anti-IL-4R antibody comprises dupilumab.

9. The pharmaceutical composition according to any one of claims 5 to 7, wherein the allergic rhinitis is a high eosinophil subset of allergic rhinitis.

Citation Information

Patent Citations

  • Anti-IL-33 antibodies and their use

    JP2016513644A

  • IL-33 antagonists and their uses

    JP2016515130A

  • Genetic Variants as Markers for Use in Diagnosis, Prognosis and Treatment of Eosinophilia, Asthma, and Myocardial Infarction

    US20100160802A1

  • Methods for treating or preventing asthma by administering an il-4r antagonist

    WO2015127229A1